



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification</b> <sup>6</sup> : <b>C07K 14/47, 14/00, 7/00, C12N 5/10, 15/10, 15/11, 15/12, 15/63, A61K 38/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/26972</b> <b>(43) International Publication Date:</b> 3 June 1999 (03.06.99)
<b>(21) International Application Number:</b> PCT/US98/24614 <b>(22) International Filing Date:</b> 17 November 1998 (17.11.98)  <b>(30) Priority Data:</b> 08/976,110 21 November 1997 (21.11.97) US 09/080,478 18 May 1998 (18.05.98) US 09/175,928 20 October 1998 (20.10.98) US  <b>(71) Applicant:</b> GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).  <b>(72) Inventors:</b> JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). COLLINS-RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). EVANS, Cheryl; 307 Brighton Drive, Beverly, MA 01915 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US).  <b>(74) Agent:</b> SPRUNGER, Suzanne, A.; American Home Products Corporation, Patent & Trademark Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM  <b>(57) Abstract</b>  Novel polynucleotides and the proteins encoded thereby are disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

## SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

This application is a continuation-in-part of the following applications: Ser. No. 08/686,878, filed July 26, 1996; Ser. No. 08/702,081, filed August 23, 1996, which is a continuation-in-part of Ser. No. 08/686,878; Ser. No. 08/721,489, filed September 27, 1996, which is a continuation-in-part of Ser. No. 08/686,878; and 08/721,924, filed September 27, 1996, which is a continuation-in-part of Ser. No. 08/686,878; all of which are incorporated by reference herein.

15

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

20

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

35

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 44 to nucleotide 1204;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 403;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ26\_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ26\_3 deposited under accession number ATCC 98115;
- 15 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ26\_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ26\_3 deposited under accession number ATCC 98115;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of
- 25 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 44 to nucleotide 1204; the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 403; the nucleotide sequence of the full-length protein coding sequence of clone AJ26\_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone AJ26\_3 deposited

under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AJ26\_3 deposited under accession number ATCC 98115. In yet other preferred  
5 comprising the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group  
10 consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120;
- (c) fragments of the amino acid sequence of SEQ ID NO:2; and
- 15 (d) the amino acid sequence encoded by the cDNA insert of clone AJ26\_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID  
25 NO:3 from nucleotide 928 to nucleotide 2541;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 988 to nucleotide 2541;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 684 to nucleotide 1128;
- 30 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ172\_2 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ172\_2 deposited under accession number ATCC 98115;

(g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ172\_2 deposited under accession number ATCC 98115;

(h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ172\_2 deposited under accession number ATCC 98115;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 928 to nucleotide 2541; the nucleotide sequence of SEQ ID NO:3 from nucleotide 988 to nucleotide 2541; the nucleotide sequence of SEQ ID NO:3 from nucleotide 684 to nucleotide 1128; the nucleotide sequence of the full-length protein coding sequence of clone AJ172\_2 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone AJ172\_2 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AJ172\_2 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67;

- (c) fragments of the amino acid sequence of SEQ ID NO:4; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AJ172\_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such  
5 protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence  
of SEQ ID NO:4 from amino acid 1 to amino acid 67.

In one embodiment, the present invention provides a composition comprising an  
isolated polynucleotide selected from the group consisting of:

- 10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID  
NO:6;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID  
NO:6 from nucleotide 185 to nucleotide 385;
- (c) a polynucleotide comprising the nucleotide sequence of the full-  
length protein coding sequence of clone AP224\_2 deposited under accession  
15 number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the  
cDNA insert of clone AP224\_2 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature  
protein coding sequence of clone AP224\_2 deposited under accession number  
20 ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the  
cDNA insert of clone AP224\_2 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid  
sequence of SEQ ID NO:7;
- 25 (h) a polynucleotide encoding a protein comprising a fragment of the  
amino acid sequence of SEQ ID NO:7 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of  
(a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein  
30 of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions  
to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID  
NO:6 from nucleotide 185 to nucleotide 385; the nucleotide sequence of the full-length

protein coding sequence of clone AP224\_2 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone AP224\_2 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AP224\_2 deposited under accession number ATCC 98115. In yet other preferred  
5       embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7 from amino acid 1 to amino acid 28.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:6, SEQ ID NO:5 or SEQ ID NO:8 .

10       In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a)     the amino acid sequence of SEQ ID NO:7;
  - (b)     the amino acid sequence of SEQ ID NO:7 from amino acid 1 to  
15       amino acid 28;
  - (c)     fragments of the amino acid sequence of SEQ ID NO:7; and
  - (d)     the amino acid sequence encoded by the cDNA insert of clone AP224\_2 deposited under accession number ATCC 98115;
- the protein being substantially free from other mammalian proteins. Preferably such  
20       protein comprises the amino acid sequence of SEQ ID NO:7 or the amino acid sequence of SEQ ID NO:7 from amino acid 1 to amino acid 28.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID  
25       NO:9;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 6 to nucleotide 2408;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1295 to nucleotide 1705;
- (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL89\_13 deposited under accession  
30       number ATCC 98153;
- (e)     a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL89\_13 deposited under accession number ATCC 98153;



(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL89\_13 deposited under accession number ATCC 98153;

5 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL89\_13 deposited under accession number ATCC 98153;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity;

10 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

15 (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 6 to nucleotide 2408; the nucleotide sequence of SEQ ID NO:9 from nucleotide 1295 to nucleotide 1705; the nucleotide sequence of the full-length protein coding sequence of clone BL89\_13 deposited under accession number ATCC 98153; or the  
20 nucleotide sequence of the mature protein coding sequence of clone BL89\_13 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BL89\_13 deposited under accession number ATCC 98153. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein  
25 comprising the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

30 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:10;

(b) the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567;

- (c) fragments of the amino acid sequence of SEQ ID NO:10; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BL89\_13 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins. Preferably such  
5 protein comprises the amino acid sequence of SEQ ID NO:10 or the amino acid sequence  
of SEQ ID NO:10 from amino acid 431 to amino acid 567.

In one embodiment, the present invention provides a composition comprising an  
isolated polynucleotide selected from the group consisting of:

- 10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID  
NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID  
NO:11 from nucleotide 2113 to nucleotide 2337;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID  
NO:11 from nucleotide 2036 to nucleotide 2316;
- 15 (d) a polynucleotide comprising the nucleotide sequence of the full-  
length protein coding sequence of clone BL341\_4 deposited under accession  
number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the  
cDNA insert of clone BL341\_4 deposited under accession number ATCC 98115;
- 20 (f) a polynucleotide comprising the nucleotide sequence of the mature  
protein coding sequence of clone BL341\_4 deposited under accession number  
ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the  
cDNA insert of clone BL341\_4 deposited under accession number ATCC 98115;
- 25 (h) a polynucleotide encoding a protein comprising the amino acid  
sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the  
amino acid sequence of SEQ ID NO:12 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of  
30 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein  
of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions  
to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 2113 to nucleotide 2337; the nucleotide sequence of SEQ ID NO:11 from nucleotide 2036 to nucleotide 2316; the nucleotide sequence of the full-length protein coding sequence of clone BL341\_4 deposited under accession number ATCC 98115; or the  
5 nucleotide sequence of the mature protein coding sequence of clone BL341\_4 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BL341\_4 deposited under accession number ATCC 98115. In yet other preferred  
10 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 68.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

In other embodiments, the present invention provides a composition comprising  
15 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 68;
- 20 (c) fragments of the amino acid sequence of SEQ ID NO:12; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BL341\_4 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12 or the amino acid sequence  
25 of SEQ ID NO:12 from amino acid 1 to amino acid 68.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- 30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1 to nucleotide 390;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV239\_3 deposited under accession number ATCC 98153;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV239\_3 deposited under accession number ATCC 98153;

(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BV239\_3 deposited under accession number ATCC 98153;

(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BV239\_3 deposited under accession number ATCC 98153;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 1 to nucleotide 390; the nucleotide sequence of the full-length protein coding sequence of clone BV239\_3 deposited under accession number ATCC 98153; or the nucleotide sequence of the mature protein coding sequence of clone BV239\_3 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BV239\_3 deposited under accession number ATCC 98153. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:14;

(b) the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130;

(c) fragments of the amino acid sequence of SEQ ID NO:14; and

(d) the amino acid sequence encoded by the cDNA insert of clone  
5 BV239\_3 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14 or the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130.

In one embodiment, the present invention provides a composition comprising an  
10 isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 144 to nucleotide 257;

15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 30 to nucleotide 271;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC25\_17 deposited under accession number ATCC 98153;

20 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC25\_17 deposited under accession number ATCC 98153;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC25\_17 deposited under accession number ATCC 98153;

25 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC25\_17 deposited under accession number ATCC 98153;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

30 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 144 to nucleotide 257; the nucleotide sequence of SEQ ID NO:15 from nucleotide 30 to nucleotide 271; the nucleotide sequence of the full-length protein coding sequence of clone CC25\_17 deposited under accession number ATCC 98153; or the nucleotide sequence of the mature protein coding sequence of clone CC25\_17 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CC25\_17 deposited under accession number ATCC 98153.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
  - (b) fragments of the amino acid sequence of SEQ ID NO:16; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone CC25\_17 deposited under accession number ATCC 98153;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 431 to nucleotide 520;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 266 to nucleotide 511;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC397\_19 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC397\_19 deposited under accession number ATCC 98153;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC397\_19 deposited under accession number ATCC 98153;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC397\_19 deposited under accession number ATCC 98153;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 431 to nucleotide 520; the nucleotide sequence of SEQ ID NO:17 from nucleotide 266 to nucleotide 511; the nucleotide sequence of the full-length protein coding sequence of clone CC397\_19 deposited under accession number ATCC 98153; or the nucleotide sequence of the mature protein coding sequence of clone CC397\_19 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CC397\_19 deposited under accession number ATCC 98153. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:18;

(b) the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27;

(c) fragments of the amino acid sequence of SEQ ID NO:18; and

(d) the amino acid sequence encoded by the cDNA insert of clone CC397\_19 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins. Preferably such

5 protein comprises the amino acid sequence of SEQ ID NO:18 or the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 253 to nucleotide 519;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 298 to nucleotide 519;

15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone D305\_2 deposited under accession number ATCC 98115;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone D305\_2 deposited under accession number ATCC 98115;

20 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone D305\_2 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone D305\_2 deposited under accession number ATCC 98115;

25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;

30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).



Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20 from nucleotide 253 to nucleotide 519; the nucleotide sequence of SEQ ID NO:20 from nucleotide 298 to nucleotide 519; the nucleotide sequence of the full-length protein coding sequence of clone D305\_2 deposited under accession number ATCC 98115; or the  
5 nucleotide sequence of the mature protein coding sequence of clone D305\_2 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone D305\_2 deposited under accession number ATCC 98115.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ  
10 ID NO:20, SEQ ID NO:19 or SEQ ID NO:22.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:21;
- 15 (b) fragments of the amino acid sequence of SEQ ID NO:21; and
- (c) the amino acid sequence encoded by the cDNA insert of clone D305\_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:21.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID  
25 NO:23 from nucleotide 194 to nucleotide 622;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 524 to nucleotide 622;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone G55\_1 deposited under accession number  
30 ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone G55\_1 deposited under accession number ATCC 98115;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone G55\_1 deposited under accession number ATCC 98115;

5 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone G55\_1 deposited under accession number ATCC 98115;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity;

10 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

15 (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 194 to nucleotide 622; the nucleotide sequence of SEQ ID NO:23 from nucleotide 524 to nucleotide 622; the nucleotide sequence of the full-length protein coding sequence of clone G55\_1 deposited under accession number ATCC 98115; or the  
20 nucleotide sequence of the mature protein coding sequence of clone G55\_1 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone G55\_1 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein  
25 comprising the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:23 or SEQ ID NO:25.

In other embodiments, the present invention provides a composition comprising  
30 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:24;

(b) the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32;

- (c) fragments of the amino acid sequence of SEQ ID NO:24; and
- (d) the amino acid sequence encoded by the cDNA insert of clone G55\_1 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such  
5 protein comprises the amino acid sequence of SEQ ID NO:24 or the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 402 to nucleotide 533;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 447 to nucleotide 533;
- 15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K39\_7 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K39\_7 deposited under accession number ATCC 98115;
- 20 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K39\_7 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K39\_7 deposited under accession number ATCC 98115;
- 25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:27;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:27 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of  
30 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:26 from nucleotide 402 to nucleotide 533; the nucleotide sequence of SEQ ID NO:26 from nucleotide 447 to nucleotide 533; the nucleotide sequence of the full-length protein coding sequence of clone K39\_7 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K39\_7 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K39\_7 deposited under accession number ATCC 98115.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:26 or SEQ ID NO:28.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:27;
- (b) fragments of the amino acid sequence of SEQ ID NO:27; and
- (c) the amino acid sequence encoded by the cDNA insert of clone K39\_7 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:27.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 241 to nucleotide 525;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K330\_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K330\_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K330\_3 deposited under accession number ATCC 98115;

(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K330\_3 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;

5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein  
10 of (g) or (h) above ; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 241 to nucleotide 525; the nucleotide sequence of the full-length  
15 protein coding sequence of clone K330\_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K330\_3 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K330\_3 deposited under accession number ATCC 98115. In yet other preferred  
20 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30 from amino acid 1 to amino acid 35.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29 or SEQ ID NO:31.

25 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:30;

(b) the amino acid sequence of SEQ ID NO:30 from amino acid 1 to  
30 amino acid 35;

(c) fragments of the amino acid sequence of SEQ ID NO:30; and

(d) the amino acid sequence encoded by the cDNA insert of clone K330\_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30 from amino acid 1 to amino acid 35.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 158 to nucleotide 571;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K363\_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K363\_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K363\_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K363\_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:32 from nucleotide 158 to nucleotide 571; the nucleotide sequence of the full-length protein coding sequence of clone K363\_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K363\_3 deposited under accession number ATCC 98115. In other preferred embodiments, the

polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K363\_3 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 96.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:32 or SEQ ID NO:34.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:33;
- (b) the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 96;
- (c) fragments of the amino acid sequence of SEQ ID NO:33; and
- (d) the amino acid sequence encoded by the cDNA insert of clone K363\_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:33 or the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 96.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 401 to nucleotide 526;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K446\_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K446\_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K446\_3 deposited under accession number ATCC 98115;

(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K446\_3 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;

5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

10 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:35 from nucleotide 401 to nucleotide 526; the nucleotide sequence of the full-length  
15 protein coding sequence of clone K446\_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K446\_3 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K446\_3 deposited under accession number ATCC 98115.

20 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:35 or SEQ ID NO:37.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

25 (a) the amino acid sequence of SEQ ID NO:36;  
(b) fragments of the amino acid sequence of SEQ ID NO:36; and  
(c) the amino acid sequence encoded by the cDNA insert of clone K446\_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such  
30 protein comprises the amino acid sequence of SEQ ID NO:36.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38;



(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38 from nucleotide 380 to nucleotide 535;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K464\_4 deposited under accession number ATCC 98115;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K464\_4 deposited under accession number ATCC 98115;

(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K464\_4 deposited under accession number ATCC 98115;

(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K464\_4 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:39;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:39 having biological activity;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:38 from nucleotide 380 to nucleotide 535; the nucleotide sequence of the full-length protein coding sequence of clone K464\_4 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K464\_4 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K464\_4 deposited under accession number ATCC 98115.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:38 or SEQ ID NO:40.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:39;
- (b) fragments of the amino acid sequence of SEQ ID NO:39; and
- (c) the amino acid sequence encoded by the cDNA insert of clone K464\_4 deposited under accession number ATCC 98115;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:39.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 218 to nucleotide 1159;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 806 to nucleotide 1159;
- 15 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 217 to nucleotide 517;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K483\_1 deposited under accession number ATCC 98115;
- 20 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K483\_1 deposited under accession number ATCC 98115;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K483\_1 deposited under accession number ATCC 98115;
- 25 (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K483\_1 deposited under accession number ATCC 98115;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity;
- 30 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 218 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:41 from nucleotide 806 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:41 from nucleotide 217 to nucleotide 517; the nucleotide sequence of the full-length protein coding sequence of clone K483\_1 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K483\_1 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K483\_1 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:42;
  - (b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100;
  - (c) fragments of the amino acid sequence of SEQ ID NO:42; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone K483\_1 deposited under accession number ATCC 98115;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42 or the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 446 to nucleotide 835;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 503 to nucleotide 835;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone L69\_3 deposited under accession number ATCC 98115;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone L69\_3 deposited under accession number ATCC 98115;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone L69\_3 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone L69\_3 deposited under accession number ATCC 98115;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 446 to nucleotide 835; the nucleotide sequence of SEQ ID NO:43 from nucleotide 503 to nucleotide 835; the nucleotide sequence of the full-length protein coding sequence of clone L69\_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone L69\_3 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone L69\_3 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:43 or SEQ ID NO:45.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

5 consisting of:

- (a) the amino acid sequence of SEQ ID NO:44;
- (b) the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93;
- (c) fragments of the amino acid sequence of SEQ ID NO:44; and
- 10 (d) the amino acid sequence encoded by the cDNA insert of clone L69\_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44 or the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93.

15 In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such
- 20 polynucleotide compositions in a suitable culture medium; and
- (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.

25 Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically

30 effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

### DETAILED DESCRIPTION

#### ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

#### Clone "AJ26\_3"

A polynucleotide of the present invention has been identified as clone "AJ26\_3". AJ26\_3 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AJ26\_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AJ26\_3 protein").

The nucleotide sequence of AJ26\_3 as presently determined is reported in SEQ ID NO:1. What applicants presently believe to be the proper reading frame and the predicted

amino acid sequence of the AJ26\_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AJ26\_3 should be approximately 2100 bp.

5       The nucleotide sequence disclosed herein for AJ26\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AJ26\_3 demonstrated at least some similarity with sequences identified as U46493 (Cloning vector pFlp recombinase gene, complete cds). The predicted amino acid sequence disclosed herein for AJ26\_3 was searched against the  
10   GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AJ26\_3 protein demonstrated at least some similarity to sequences identified as J01917 (DNA polymerase [Human adenovirus type 2]), J01969 (DNA polymerase [Human adenovirus type 5]), L24893 (HUMAAC02\_1 myelin protein zero [Homo sapiens]), U43330 (CTX [Xenopus laevis]), and U43394 (CTX [Xenopus laevis]).  
15   Based upon sequence similarity, AJ26\_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the AJ26\_3 protein sequence, centered around amino acids 11, 41, 163, and 246 of SEQ ID NO:2. The AJ26\_3 protein also has a possible signal sequence that could be cleaved to produce a mature protein starting at amino acid 17 of  
20   SEQ ID NO:2.

#### Clone "AJ172\_2"

A polynucleotide of the present invention has been identified as clone "AJ172\_2". AJ172\_2 was isolated from a human adult testes cDNA library using methods which are  
25   selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AJ172\_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AJ172\_2 protein").

30       The nucleotide sequence of AJ172\_2 as presently determined is reported in SEQ ID NO:3. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AJ172\_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 8 to 20 are a predicted

leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AJ172\_2 should be approximately 3000 bp.

5        The nucleotide sequence disclosed herein for AJ172\_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AJ172\_2 demonstrated at least some similarity with sequences identified as AA077794 (7H01C09 Chromosome 7 HeLa cDNA Library Homo sapiens cDNA clone 7H01C09), AC000064 (Human BAC clone RG083M05 from 7q21-7q22, 10 complete sequence), D78692 (Human placenta cDNA 5'-end GEN-503H08), H12439 (yj11h10.r1 Homo sapiens cDNA clone 148483 5'), R27389 (yh46a09.s1 Homo sapiens cDNA clone 132760 3'), and T09280 (Novel AMP/MCF virus clone 24 genome). The predicted amino acid sequence disclosed herein for AJ172\_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. 15 The predicted AJ172\_2 protein demonstrated at least some similarity to sequences identified as M26927 (pol polyprotein [Gibbon leukemia virus]), M93134 (pol protein [Friend murine leukemia virus]), and R75189 (Osteoinductive retrovirus RFB-14 pol gene product). AJ172\_2 protein is similar to a number of viral env proteins, including those of baboon endogenous virus and many leukemia viruses, which associate with the 20 membrane portion of the viral envelope. Based upon sequence similarity, AJ172\_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five potential transmembrane domains within the AJ172\_2 protein sequence, centered around amino acids 104, 267, 292, 328, and 457 of SEQ ID NO:4.

25

#### Clone "AP224\_2"

A polynucleotide of the present invention has been identified as clone "AP224\_2". AP224\_2 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was 30 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AP224\_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AP224\_2 protein").



The nucleotide sequence of the 5' portion of AP224\_2 as presently determined is reported in SEQ ID NO:5. An additional internal nucleotide sequence from AP224\_2 as presently determined is reported in SEQ ID NO:6. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:7. Additional nucleotide sequence from the 3' portion of AP224\_2, including the polyA tail, is reported in SEQ ID NO:8.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AP224\_2 should be approximately 2100 bp.

The nucleotide sequence disclosed herein for AP224\_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AP224\_2 demonstrated at least some similarity with sequences identified as R37675 (yf61f08.s1 Homo sapiens cDNA clone 26687 3'). Based upon sequence similarity, AP224\_2 proteins and each similar protein or peptide may share at least some activity.

#### Clone "BL89\_13"

A polynucleotide of the present invention has been identified as clone "BL89\_13". BL89\_13 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BL89\_13 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL89\_13 protein").

The nucleotide sequence of BL89\_13 as presently determined is reported in SEQ ID NO:9. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BL89\_13 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BL89\_13 should be approximately 3200 bp.

The nucleotide sequence disclosed herein for BL89\_13 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The TopPredII computer program predicts a potential transmembrane domain within the BL89\_13 protein sequence centered around amino acid 625 of SEQ ID NO:10.

Clone "BL341\_4"

A polynucleotide of the present invention has been identified as clone "BL341\_4". BL341\_4 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BL341\_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL341\_4 protein").

The nucleotide sequence of BL341\_4 as presently determined is reported in SEQ ID NO:11. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BL341\_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BL341\_4 should be approximately 2600 bp.

The nucleotide sequence disclosed herein for BL341\_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BL341\_4 demonstrated at least some similarity with sequences identified as AA460103 (zx50a12.r1 Soares testis NHT Homo sapiens cDNA clone) and Z63359 (H.sapiens CpG island DNA genomic MseI fragment, clone 81e7, reverse read cpg81e7.rt1a). Based upon sequence similarity, BL341\_4 proteins and each similar protein or peptide may share at least some activity.

Clone "BV239\_3"

A polynucleotide of the present invention has been identified as clone "BV239\_3". BV239\_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV239\_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV239\_3 protein").

The nucleotide sequence of BV239\_3 as presently determined is reported in SEQ ID NO:13. What applicants presently believe to be the proper reading frame and the

predicted amino acid sequence of the BV239\_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV239\_3 should be approximately 310 bp.

5       The nucleotide sequence disclosed herein for BV239\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV239\_3 demonstrated at least some similarity with sequences identified as U46493 (Cloning vector pFlp recombinase gene, complete cds). Based upon sequence similarity, BV239\_3 proteins and each similar protein or peptide may share at  
10   least some activity.

Clone "CC25\_17"

A polynucleotide of the present invention has been identified as clone "CC25\_17". CC25\_17 was isolated from a human adult brain cDNA library using methods which are  
15   selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CC25\_17 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC25\_17 protein").

20       The nucleotide sequence of CC25\_17 as presently determined is reported in SEQ ID NO:15. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC25\_17 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
25   CC25\_17 should be approximately 300 bp.

The nucleotide sequence disclosed herein for CC25\_17 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC25\_17 demonstrated at least some similarity with sequences identified as U46493 (Cloning vector pFlp recombinase gene, complete cds). Based upon  
30   sequence similarity, CC25\_17 proteins and each similar protein or peptide may share at least some activity.

Clone "CC397\_19"

A polynucleotide of the present invention has been identified as clone "CC397\_19". CC397\_19 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was  
5 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CC397\_19 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC397\_19 protein").

The nucleotide sequence of CC397\_19 as presently determined is reported in SEQ  
10 ID NO:17. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC397\_19 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CC397\_19 should be approximately 1700 bp.

15 The nucleotide sequence disclosed herein for CC397\_19 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC397\_19 demonstrated at least some similarity with sequences identified as AC002129 (Human DNA from chromosome 19 cosmid R33743, genomic sequence, complete sequence), D82019 (Mouse gene for basigin precursor, basigin signal  
20 precursor), G08688 (human STS CHLC.GATA29D08.P14592 clone GATA29D08), M68516 (Human protein C inhibitor gene, complete cds), and Z68756 (Human DNA sequence from cosmid L191F1, Huntington's Disease Region, chromosome 4p16.3 contains Huntington Disease (HD) gene, CpG island ESTs and U7 small nuclear RNA). The predicted amino acid sequence disclosed herein for CC397\_19 was searched against the  
25 GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CC397\_19 protein demonstrated at least some similarity to sequences identified as X52164 (Q300 protein (AA 1-77) [Mus musculus]). Based upon sequence similarity, CC397\_19 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CC397\_19 indicates that it may contain an Alu  
30 repetitive element.

Clone "D305\_2"

A polynucleotide of the present invention has been identified as clone "D305\_2". D305\_2 was isolated from a human adult blood (peripheral blood mononuclear cells

treated with concanavalin A and phorbol myristate acetate) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. D305\_2 is a full-length clone,  
5 including the entire coding sequence of a secreted protein (also referred to herein as "D305\_2 protein").

The nucleotide sequence of the 5' portion of D305\_2 as presently determined is reported in SEQ ID NO:19. An additional internal nucleotide sequence from D305\_2 as presently determined is reported in SEQ ID NO:20. What applicants believe is the proper  
10 reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:21. Amino acids 3 to 15 of SEQ ID NO:21 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of D305\_2, including the polyA tail, is reported in SEQ ID NO:22.

15 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone D305\_2 should be approximately 2400 bp.

The nucleotide sequence disclosed herein for D305\_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. D305\_2 demonstrated at least some similarity with sequences  
20 identified as AA055703 (zl75d04.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 510439 5'), N49593 (yy58d05.s1 Homo sapiens cDNA clone 277737 3'), R66646 (yi35b08.r1 Homo sapiens cDNA clone 141207 5' similar to SP P24A\_YEAST P32802 P24A PROTEIN), U81006 (Human p76 mRNA, complete cds), and Z48758 (S.cerevisiae chromosome IV cosmid 9727). The predicted amino acid sequence disclosed herein for D305\_2 was  
25 searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted D305\_2 protein demonstrated at least some similarity to sequences identified as U53880 (P24A protein (unknown function) (Swiss Prot. accession number P32802) [Saccharomyces cerevisiae]), U81006 (p76 [Homo sapiens]), X67316 (SCEMP70\_1 p24a 70 kDa precursor [Saccharomyces cerevisiae]), and  
30 Z48758 (unknown [Saccharomyces cerevisiae]). Based upon sequence similarity, D305\_2 proteins and each similar protein or peptide may share at least some activity.

Clone "G55\_1"

A polynucleotide of the present invention has been identified as clone "G55\_1". G55\_1 was isolated from a human adult blood (peripheral blood mononuclear cells treated with concanavalin A and phorbol myristate acetate) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. G55\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "G55\_1 protein").

10 The nucleotide sequence of the 5' portion of G55\_1 as presently determined is reported in SEQ ID NO:23. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:24. The predicted amino acid sequence of the G55\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 98 to 110 are a predicted leader/signal sequence, with the  
15 predicted mature amino acid sequence beginning at amino acid 111, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of G55\_1, including the polyA tail, is reported in SEQ ID NO:25.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone G55\_1 should be approximately 2000 bp.

20 The nucleotide sequence disclosed herein for G55\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. G55\_1 demonstrated at least some similarity with sequences identified as R83586 (yp16a07.r1 Homo sapiens cDNA clone 187572 5'). Based upon sequence similarity, G55\_1 proteins and each similar protein or peptide may share at least  
25 some activity.

Clone "K39\_7"

A polynucleotide of the present invention has been identified as clone "K39\_7". K39\_7 was referred to as K39\_2 in previous applications. K39\_7 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K39\_7 is a full-length clone,  
30

including the entire coding sequence of a secreted protein (also referred to herein as "K39\_7 protein").

The nucleotide sequence of the 5' portion of K39\_7 as presently determined is reported in SEQ ID NO:26. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:27. The predicted amino acid sequence of the K39\_7 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:27. Amino acids 3 to 15 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of K39\_7, including the polyA tail, is reported in SEQ ID NO:28.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K39\_7 should be approximately 1675 bp.

The nucleotide sequence disclosed herein for K39\_7 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K39\_7 demonstrated at least some similarity with sequences identified as AA254326 (va15d06.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 722987 5' similar to WP:C09G4.1 CE03978), D18935 (Mouse 3'-directed cDNA, MUSGS01125, clone mc0564), H14129 (ym65b04.r1 Homo sapiens cDNA clone 163759 5'), and R20230 (hUOG-1, DNA segment encoding a mammalian GDF-1 protein). The predicted amino acid sequence disclosed herein for K39\_7 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted K39\_7 protein demonstrated at least some similarity to sequences identified as R86811 (Saccharomyces cerevisiae mutant LAG1 protein) and U42438 (similar to S. cerevisiae longevity-assurance protein 1 (SP P38703) [Caenorhabditis elegans]). Based upon sequence similarity, K39\_7 proteins and each similar protein or peptide may share at least some activity.

#### Clone "K330\_3"

A polynucleotide of the present invention has been identified as clone "K330\_3". K330\_3 was referred to as K330\_2 in previous applications. K330\_3 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K330\_3 is a full-length clone,

including the entire coding sequence of a secreted protein (also referred to herein as "K330\_3 protein").

The nucleotide sequence of the 5' portion of K330\_3 as presently determined is reported in SEQ ID NO:29. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:30. The predicted amino acid sequence of the K330\_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Additional nucleotide sequence from the 3' portion of K330\_3, including the polyA tail, is reported in SEQ ID NO:31.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K330\_3 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for K330\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K330\_3 demonstrated at least some similarity with sequences identified as A03900 (H.sapiens HuV(NP) gene), AA038010 (mi80a11.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 472892 5'), M30775 (Mouse thymidylate synthase pseudogene, 3' flank), R40824 (yf82c07.s1 Homo sapiens cDNA clone 28939 3'), T23245 (Human gene signature HUMGS05046), and U23512 (Caenorhabditis elegans cosmid M01G4). Based upon sequence similarity, K330\_3 proteins and each similar protein or peptide may share at least some activity.

20

#### Clone "K363\_3"

A polynucleotide of the present invention has been identified as clone "K363\_3". K363\_3 was referred to as K363\_2 in previous applications. K363\_3 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K363\_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "K363\_3 protein").

The nucleotide sequence of the 5' portion of K363\_3 as presently determined is reported in SEQ ID NO:32. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:33. The predicted amino acid sequence of the K363\_3 protein corresponding to the foregoing nucleotide sequence is reported in



SEQ ID NO:33. Additional nucleotide sequence from the 3' portion of K363\_3, including the polyA tail, is reported in SEQ ID NO:34.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K363\_3 should be approximately 2690 bp.

5       The nucleotide sequence disclosed herein for K363\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K363\_3 demonstrated at least some similarity with sequences identified as AA437876 (vd20h06.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone 793115 5'), D21554 (Mouse embryonal carcinoma F9 cell cDNA, 67F09), and Y08460  
10       (Mus musculus mRNA for Mdes transmembrane protein). The predicted amino acid sequence disclosed herein for K363\_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted K363\_3 protein demonstrated at least some similarity to sequences identified as Y08460 (Mdes protein [Mus musculus]). Based upon sequence similarity, K363\_3 proteins and each  
15       similar protein or peptide may share at least some activity.

#### Clone "K446\_3"

A polynucleotide of the present invention has been identified as clone "K446\_3". K446\_3 was referred to as K446\_2 in previous applications. K446\_3 was isolated from a  
20       murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K446\_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as  
25       "K446\_3 protein").

The nucleotide sequence of the 5' portion of K446\_3 as presently determined is reported in SEQ ID NO:35. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:36. The predicted amino acid sequence of the K446\_3 protein corresponding to the foregoing nucleotide sequence is reported in  
30       SEQ ID NO:36. Additional nucleotide sequence from the 3' portion of K446\_3, including the polyA tail, is reported in SEQ ID NO:37.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K446\_3 should be approximately 2150 bp.

The nucleotide sequence disclosed herein for K446\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

5        Clone "K464\_4"

A polynucleotide of the present invention has been identified as clone "K464\_4". K464\_4 was referred to as K464\_3 in previous applications. K464\_4 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was  
10 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K464\_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "K464\_4 protein").

The nucleotide sequence of the 5' portion of K464\_4 as presently determined is  
15 reported in SEQ ID NO:38. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:39. The predicted amino acid sequence of the K464\_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:39. Additional nucleotide sequence from the 3' portion of K464\_4, including the polyA tail, is reported in SEQ ID NO:40.

20        The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K464\_4 should be approximately 1250 bp.

The nucleotide sequence disclosed herein for K464\_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K464\_4 demonstrated at least some similarity with sequences  
25 identified as AA260484 (va95a09.r1 Soares mouse NML Mus musculus cDNA clone 747160 5'), AA419864 (vf49b08.r1 Soares mouse NbM), L25338 (Mus musculus folate-binding protein gene, 5' end), M22527 (Mouse cytotoxic T lymphocyte-specific serine protease), T01176 (P815A antigen precursor gene P1A), T21224 (Human gene signature HUMGS02538), T41900 (Vector pAPEX-3p), U46493 (Cloning vector pFlp recombinase gene, complete cds), U89673 (Cloning vector pIRES1neo, complete plasmid  
30 sequence), W32699 (zc06b11.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 321501 3'), and W36926 (mb82b10.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 335899 5'). The predicted amino acid sequence disclosed herein for K464\_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the

BLASTX search protocol. The predicted K464\_4 protein demonstrated at least some similarity to sequences identified as L33768 (JAK3 [Mus musculus]) and X16213 (MHC T7 class I antigen (64 AA) (119 is 2nd base in codon) [Mus musculus]). Based upon sequence similarity, K464\_4 proteins and each similar protein or peptide may share at least some activity.

#### Clone "K483\_1"

A polynucleotide of the present invention has been identified as clone "K483\_1". K483\_1 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K483\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "K483\_1 protein").

The nucleotide sequence of K483\_1 as presently determined is reported in SEQ ID NO:41. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the K483\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 184 to 196 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 197, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K483\_1 should be approximately 1500 bp.

The nucleotide sequence disclosed herein for K483\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K483\_1 demonstrated at least some similarity with sequences identified as AA110914 (mm02c03.r1 Stratagene mouse kidney (#937315) Mus musculus cDNA clone 520324 5'), AA318160 (EST20431 Retina II Homo sapiens cDNA 5' end), AA500150 (vi97c09.r1 Barstead mouse pooled organs MPLRB4 Mus musculus cDNA clone 920176 5'), and N41895 (yw86b03.r1 Homo sapiens cDNA clone 259085 5'). Based upon sequence similarity, K483\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the K483\_1 protein sequence, centered around amino acids 18, 179, and 270 of SEQ ID NO:42. The K483\_1 protein also has a possible signal

sequence that could be cleaved to produce a mature protein starting at amino acid 34 of SEQ ID NO:42.

Clone "L69\_3"

5 A polynucleotide of the present invention has been identified as clone "L69\_3". L69\_3 was referred to as L69\_2 in previous applications. L69\_3 was isolated from a murine adult thymus cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid  
10 sequence of the encoded protein. L69\_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "L69\_3 protein").

The nucleotide sequence of the 5' portion of L69\_3 as presently determined is reported in SEQ ID NO:43. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:44. The predicted amino acid sequence  
15 of the L69\_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:44. Amino acids 7 to 19 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of L69\_3, including the polyA tail, is reported in SEQ ID NO:45.

20 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone L69\_3 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for L69\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. L69\_3 demonstrated at least some similarity with sequences  
25 identified as H35162 (EST108034 Rattus sp. cDNA similar to H.sapiens hypothetical protein (PIR:S25641)), U02442 (Cloning vector pADbeta, complete sequence), W74864 (md91b10.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA), and X67698 (H.sapiens tissue specific mRNA). The predicted amino acid sequence disclosed herein for L69\_3 was searched against the GenPept and GeneSeq amino acid sequence databases  
30 using the BLASTX search protocol. The predicted L69\_3 protein demonstrated at least some similarity to sequences identified as A18921 (tissue-specific secretory protein [unidentified]). Based upon sequence similarity, L69\_3 proteins and each similar protein or peptide may share at least some activity.

Deposit of Clones

Clones AJ26\_3, AJ172\_2, AP224\_2, BL89\_10, BL341\_4, BV239\_2, CC25\_16, CC397\_11, D305\_2, G55\_1, K39\_7, K330\_3, K363\_3, K446\_3, K464\_4, K483\_1, and L69\_3 were deposited on July 25, 1996 with the American Type Culture Collection as an original deposit under the Budapest Treaty and were given the accession number ATCC 98115, from which each clone comprising a particular polynucleotide is obtainable. Clones K39\_7, K330\_3, K363\_3, K446\_3, K464\_4, and L69\_3 were referred to as K39\_2, K330\_2, K363\_2, K446\_2, K464\_3, and L69\_2, respectively, when the July 25, 1996 deposit was made. An additional isolate of each of clones BL89\_10, BV239\_2, CC25\_16, and CC397\_11 (namely isolates BL89\_13, BV239\_3, CC25\_17, and CC397\_19, respectively) were deposited with the American Type Culture Collection on August 23, 1996 under accession number 98153, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b).

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Fig. 1. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences

provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	<u>Clone</u>	<u>Probe Sequence</u>
5	AJ26_3	SEQ ID NO:46
	AJ172_2	SEQ ID NO:47
	AP224_2	SEQ ID NO:48
	BL89_13	SEQ ID NO:49
10	BL341_4	SEQ ID NO:50
	BV239_3	SEQ ID NO:51
	CC25_17	SEQ ID NO:52
	CC397_19	SEQ ID NO:53
	D305_2	SEQ ID NO:54
15	G55_1	SEQ ID NO:55
	K39_7	SEQ ID NO:56
	K330_3	SEQ ID NO:57
	K363_3	SEQ ID NO:58
	K446_3	SEQ ID NO:59
20	K464_4	SEQ ID NO:60
	K483_1	SEQ ID NO:61
	L69_3	SEQ ID NO:62

25 In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

30 The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a  $T_m$  of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with g-<sup>32</sup>P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmol.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 µl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 µg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the cDNA sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which the cDNA sequences are derived and any contiguous regions of the genome necessary for the regulated expression of such genes, including but not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials.

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and



transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide, as determined by those of skill in the art. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) <sup>†</sup>	Hybridization Temperature and Buffer <sup>†</sup>	Wash Temperature and Buffer <sup>†</sup>
5	A	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	<50	T <sub>B</sub> *; 1xSSC	T <sub>B</sub> *; 1xSSC
	C	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	<50	T <sub>D</sub> *; 1xSSC	T <sub>D</sub> *; 1xSSC
	E	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	<50	T <sub>F</sub> *; 1xSSC	T <sub>F</sub> *; 1xSSC
10	G	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	<50	T <sub>H</sub> *; 4xSSC	T <sub>H</sub> *; 4xSSC
	I	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	<50	T <sub>J</sub> *; 4xSSC	T <sub>J</sub> *; 4xSSC
	K	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	<50	T <sub>L</sub> *; 2xSSC	T <sub>L</sub> *; 2xSSC
15	M	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	<50	T <sub>N</sub> *; 6xSSC	T <sub>N</sub> *; 6xSSC
	O	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	<50	T <sub>P</sub> *; 6xSSC	T <sub>P</sub> *; 6xSSC
	Q	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	R	<50	T <sub>R</sub> *; 4xSSC	T <sub>R</sub> *; 4xSSC

<sup>†</sup>: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

<sup>†</sup>: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH<sub>2</sub>PO<sub>4</sub>, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

\*T<sub>B</sub> - T<sub>R</sub>: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T<sub>m</sub>) of the hybrid, where T<sub>m</sub> is determined according to the following equations. For hybrids less than 18 base pairs in length, T<sub>m</sub>(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T<sub>m</sub>(°C) = 81.5 + 16.6(log<sub>10</sub>[Na<sup>+</sup>]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na<sup>+</sup>] is the concentration of sodium ions in the hybridization buffer ([Na<sup>+</sup>] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *e.g.*, Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (*i.e.*, from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, *e.g.*, silica gel having pendant

methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

## USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

### Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which

the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

#### Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

#### Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays

for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured  
5 by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter  
10 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node  
15 cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon  $\gamma$ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

20 Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature*  
25 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;  
30 Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.



Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

#### Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for

example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an  
5 immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves  
10 inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

15 Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue  
20 transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a  
25 monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an  
30 immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or

tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of

viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I  $\alpha$  chain protein and  $\beta_2$  microglobulin protein or an MHC class II  $\alpha$  chain protein and an MHC class II  $\beta$  chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.

Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (*e.g.*, B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

10           The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, *Immunologic studies in Humans*); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnoli et al., *Cellular Immunology* 133:327-341, 1991; Brown et al., *J. Immunol.* 153:3079-3092, 1994.

25           Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

30           Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter

7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

#### Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent

myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland,

H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

#### Tissue Growth Activity

5           A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

10           A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of  
15 congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

          A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce  
20 differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

25           Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and  
30 other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of



congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce  
5 differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in  
10 the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve  
15 tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present  
20 invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of  
25 non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac)  
30 and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting  
5 differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described  
10 in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ).

Assays for wound healing activity include, without limitation, those described in:  
Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year  
15 Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

#### Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related  
20 activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin  $\alpha$  family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals  
25 and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- $\beta$  group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example,  
30 United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., *Endocrinology* 91:562-572, 1972; Ling et al., *Nature* 321:779-782, 1986; Vale et al., *Nature* 321:776-779, 1986; Mason et al., *Nature* 318:659-663, 1985; Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095, 1986.

5

#### Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.

10 Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses  
15 against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population  
20 of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent  
25 chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene  
30 Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. *J. Clin. Invest.* 95:1370-1376, 1995; Lind et al. *APMIS* 103:140-146, 1995; Muller et al. *Eur. J. Immunol.* 25: 1744-1748; Gruber et al. *J. of Immunol.* 152:5860-5867, 1994; Johnston et al. *J. of Immunol.* 153: 1762-1768, 1994.

### Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins  
15 35:467-474, 1988.

### Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of  
20 such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and  
25 development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

30 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and

Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 5 1995.

#### Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in 10 the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat 15 inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting 20 from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

#### Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major 25 roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

30 The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the

first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

5 E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to  
10 their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention  
15 encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue  
20 in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and  
25 polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the  
30 cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used

to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides  
5 encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

#### 10 Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or  
15 tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

#### 20 Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height,  
25 weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein,  
30 carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic

lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen

5 in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

### ADMINISTRATION AND DOSING

10 A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term

15 "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,

20 IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention,

25 or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

30 A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.



The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be

administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred

pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.

Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01  $\mu$ g to about 100 mg (preferably about 0.1ng to about 10 mg, more preferably about 0.1  $\mu$ g to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal

antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting  
5 and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When  
10 administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also  
15 optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the  
20 developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular  
25 application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins  
30 or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-

aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.

5 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, 10 ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 15 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

20 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- $\alpha$  and TGF- $\beta$ ), and insulin-like growth factor (IGF).

25 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering 30 various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in

the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline  
5 labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without  
10 limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

15 Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. A composition comprising an isolated polynucleotide selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
  - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 44 to nucleotide 1204;
  - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 403;
  - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ26\_3 deposited under accession number ATCC 98115;
  - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ26\_3 deposited under accession number ATCC 98115;
  - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ26\_3 deposited under accession number ATCC 98115;
  - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ26\_3 deposited under accession number ATCC 98115;
  - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
  - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
  - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
  - (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
2. A composition of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with a composition of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by a composition of claim 2, which process comprises:
  - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
  - (b) purifying said protein from the culture.

6. A protein produced according to the process of claim 5.
7. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:2;
  - (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120;
  - (c) fragments of the amino acid sequence of SEQ ID NO:2; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone AJ26\_3 deposited under accession number ATCC 98115;the protein being substantially free from other mammalian proteins.
8. The composition of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
9. The composition of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.
10. A composition of claim 7, further comprising a pharmaceutically acceptable carrier.
11. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 10.
12. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:1.
13. A composition comprising an isolated polynucleotide selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
  - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 928 to nucleotide 2541;
  - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 988 to nucleotide 2541;
  - (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 684 to nucleotide 1128;
  - (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ172\_2 deposited under accession number ATCC 98115;
  - (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ172\_2 deposited under accession number ATCC 98115;



(g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ172\_2 deposited under accession number ATCC 98115;

(h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ172\_2 deposited under accession number ATCC 98115;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

14. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67;

(c) fragments of the amino acid sequence of SEQ ID NO:4; and

(d) the amino acid sequence encoded by the cDNA insert of clone AJ172\_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

15. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.

16. A composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 185 to nucleotide 385;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AP224\_2 deposited under accession number ATCC 98115;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AP224\_2 deposited under accession number ATCC 98115;

(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AP224\_2 deposited under accession number ATCC 98115;

- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AP224\_2 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

17. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:7;
  - (b) the amino acid sequence of SEQ ID NO:7 from amino acid 1 to amino acid 28;
  - (c) fragments of the amino acid sequence of SEQ ID NO:7; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone AP224\_2 deposited under accession number ATCC 98115;
- the protein being substantially free from other mammalian proteins.

18. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:8 .

19. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 6 to nucleotide 2408;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1295 to nucleotide 1705;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL89\_13 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL89\_13 deposited under accession number ATCC 98153;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL89\_13 deposited under accession number ATCC 98153;

- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL89\_13 deposited under accession number ATCC 98153;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

20. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
  - (b) the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567;
  - (c) fragments of the amino acid sequence of SEQ ID NO:10; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone BL89\_13 deposited under accession number ATCC 98153;
- the protein being substantially free from other mammalian proteins.

21. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:9.

22. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2113 to nucleotide 2337;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2036 to nucleotide 2316;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL341\_4 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL341\_4 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL341\_4 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL341\_4 deposited under accession number ATCC 98115;

- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

23. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
  - (b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 68;
  - (c) fragments of the amino acid sequence of SEQ ID NO:12; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone BL341\_4 deposited under accession number ATCC 98115;
- the protein being substantially free from other mammalian proteins.

24. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:11.

25. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1 to nucleotide 390;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV239\_3 deposited under accession number ATCC 98153;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV239\_3 deposited under accession number ATCC 98153;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BV239\_3 deposited under accession number ATCC 98153;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BV239\_3 deposited under accession number ATCC 98153;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity;

- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

26. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
  - (b) the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130;
  - (c) fragments of the amino acid sequence of SEQ ID NO:14; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone BV239\_3 deposited under accession number ATCC 98153;
- the protein being substantially free from other mammalian proteins.

27. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:13.

28. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 144 to nucleotide 257;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 30 to nucleotide 271;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC25\_17 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC25\_17 deposited under accession number ATCC 98153;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC25\_17 deposited under accession number ATCC 98153;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC25\_17 deposited under accession number ATCC 98153;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity;

- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

29. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
  - (b) fragments of the amino acid sequence of SEQ ID NO:16; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone CC25\_17 deposited under accession number ATCC 98153;
- the protein being substantially free from other mammalian proteins.

30. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:15.

31. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 431 to nucleotide 520;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 266 to nucleotide 511;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC397\_19 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC397\_19 deposited under accession number ATCC 98153;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC397\_19 deposited under accession number ATCC 98153;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC397\_19 deposited under accession number ATCC 98153;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

32. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
  - (b) the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27;
  - (c) fragments of the amino acid sequence of SEQ ID NO:18; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone CC397\_19 deposited under accession number ATCC 98153;
- the protein being substantially free from other mammalian proteins.

33. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:17.

34. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 253 to nucleotide 519;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 298 to nucleotide 519;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone D305\_2 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone D305\_2 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone D305\_2 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone D305\_2 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

35. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:21;
- (b) fragments of the amino acid sequence of SEQ ID NO:21; and
- (c) the amino acid sequence encoded by the cDNA insert of clone

D305\_2 deposited under accession number ATCC 98115;  
the protein being substantially free from other mammalian proteins.

36. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:22 .

37. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 194 to nucleotide 622;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 524 to nucleotide 622;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone G55\_1 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone G55\_1 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone G55\_1 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone G55\_1 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

38. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:24;



- (b) the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32;
  - (c) fragments of the amino acid sequence of SEQ ID NO:24; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone G55\_1 deposited under accession number ATCC 98115;
- the protein being substantially free from other mammalian proteins.

39. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:23 and SEQ ID NO:25.

40. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 402 to nucleotide 533;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 447 to nucleotide 533;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K39\_7 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K39\_7 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K39\_7 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K39\_7 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:27;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:27 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

41. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:27;
- (b) fragments of the amino acid sequence of SEQ ID NO:27; and

(c) the amino acid sequence encoded by the cDNA insert of clone K39\_7 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.

42. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:26 and SEQ ID NO:28.

43. A composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 241 to nucleotide 525;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K330\_3 deposited under accession number ATCC 98115;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K330\_3 deposited under accession number ATCC 98115;

(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K330\_3 deposited under accession number ATCC 98115;

(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K330\_3 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

44. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:30;

(b) the amino acid sequence of SEQ ID NO:30 from amino acid 1 to amino acid 35;

(c) fragments of the amino acid sequence of SEQ ID NO:30; and

(d) the amino acid sequence encoded by the cDNA insert of clone

K330\_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

45. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:29 and SEQ ID NO:31.

46. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 158 to nucleotide 571;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K363\_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K363\_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K363\_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K363\_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

47. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:33;
- (b) the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 96;
- (c) fragments of the amino acid sequence of SEQ ID NO:33; and
- (d) the amino acid sequence encoded by the cDNA insert of clone

K363\_3 deposited under accession number ATCC 98115;  
the protein being substantially free from other mammalian proteins..

48. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:32 and SEQ ID NO:34.

49. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 401 to nucleotide 526;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K446\_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K446\_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K446\_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K446\_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

50. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:36;
- (b) fragments of the amino acid sequence of SEQ ID NO:36; and
- (c) the amino acid sequence encoded by the cDNA insert of clone

K446\_3 deposited under accession number ATCC 98115;  
the protein being substantially free from other mammalian proteins.

51. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:35 and SEQ ID NO:37.

52. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38 from nucleotide 380 to nucleotide 535;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K464\_4 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K464\_4 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K464\_4 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K464\_4 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:39;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:39 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

53. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:39;
  - (b) fragments of the amino acid sequence of SEQ ID NO:39; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone K464\_4 deposited under accession number ATCC 98115;
- the protein being substantially free from other mammalian proteins.

54. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:38 and SEQ ID NO:40.

55. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 218 to nucleotide 1159;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 806 to nucleotide 1159;

- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 217 to nucleotide 517;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K483\_1 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K483\_1 deposited under accession number ATCC 98115;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K483\_1 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K483\_1 deposited under accession number ATCC 98115;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

56. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:42;
- (b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100;
- (c) fragments of the amino acid sequence of SEQ ID NO:42; and
- (d) the amino acid sequence encoded by the cDNA insert of clone K483\_1 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

57. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:41.

58. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 446 to nucleotide 835;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 503 to nucleotide 835;


- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone L69\_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone L69\_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone L69\_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone L69\_3 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

59. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:44;
  - (b) the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93;
  - (c) fragments of the amino acid sequence of SEQ ID NO:44; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone L69\_3 deposited under accession number ATCC 98115;
- the protein being substantially free from other mammalian proteins.

60. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:43 and SEQ ID NO:45.

FIGURE 1A




**Plasmid name:** pED6dpc2

**Plasmid size:** 5374 bp

**Comments/References:** pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.



FIGURE 1B



**Plasmid name:** pNOTs

**Plasmid size:** 4529 bp

**Comments/References:** pNOTs is a derivative of pMT2 (Kaufman et al, 1989. Mol. Cell. Biol. 9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the Clal site. SST cDNAs are cloned between EcoRI and NotI

## SEQUENCE LISTING

<110> Jacobs, Kenneth  
 McCoy, John M.  
 LaVallie, Edward R.  
 Collins-Racie, Lisa A.  
 Evans, Cheryl  
 Merberg, David  
 Treacy, Maurice  
 Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> 6006B-PCT

<140>

<141>

<160> 62

<170> PatentIn Ver. 2.0

<210> 1

<211> 2166

<212> DNA

<213> Homo sapiens

<400> 1

```

ggcaagctac tggcacctgc tgctctcaac taacctccac acaatggtgt tcgcattttg 60
gaaggtcttt ctgacccctaa gctgccttgc aggtcaggtt agtgtggtgc aagtgaccat 120
cccagacggg ttctgtgaacg tgactgttgg atctaattgc actctcatct gcactctaac 180
caccactgtg gctctcccgag aacagctttc catccagtgg tctttcttcc ataagaagga 240
gatggagcca atttctattt acttttctca aggtggacaa gctgtagcca tcgggcaatt 300
taaagatcga attacagggg ccaacgatcc aggtaatgca tctatcacta tctcgcatat 360
gcagccagca gacagtggaa tttacatctg cgatgttaac aacccccag actttctcgg 420
ccaaaaccaa ggcacccctca acgtcagtgt gttagtgaac ccttctaagc cctttttag 480
cgttcaagga agaccagaaa ctggccacac tatttccctt tctgtctct ctgcgcttgg 540
aacaccttcc cctgtgtact actggcataa acttgaggga agagacatcg tgccagtga 600
agaaaacttc aacccaacca ccgggatttt ggtcattgga aatctgacaa attttgaaca 660
aggttattac cagtgtactg ccatcaacag acttggaat agttcctgag aaatcgatct 720
cacttcttca catccagaag ttggaatcat tgttggggcc ttgattggtg gcttggtagg 780
tgccgccatc atcatctctg ttgtgtgctt cgcaagggaat aaggcaaaag caaaggcaaa 840
agaaagaaat tctaagacca tcgcgggaact tgagccaatg acaaagataa acccaagggg 900
agaaagcgaa gcaatgcaa gagaagacgc taccctaact gaagtaactc taccatcttc 960
cattcatgag actggccctg ataccatcca agaaccagac tatgagccaa agcctactca 1020
ggagcctgcc ccagagcctg cccagagatc agagcctatg gcagtgcctg accttgacat 1080
cgagctggag ctggagccag aaacgcagtc ggaattggag ccagagccag agccagagcc 1140
agagtcagag cctgggggtg tagttgagcc cttaagtga gatgaaaagg gagtgggtta 1200
ggcataggct ggtggcctaa gtacagcatt aatcattaa gaaccatta ctgccatttg 1260
gaattcaaat aacctaacca acctccacct cctccttcca ttttgacaa ccttcttcta 1320
acaaggtgct cattcctact atgaatccag aataaacacg ccaagataac agctaaatca 1380
gcaagggttc ctgtattacc aatatagaat actaacaatt ttactaacac gtaagcataa 1440
caaatgcagc ggcaagtgat ttctaactta gttgagtttt gcaacagtac ctgtgttgtt 1500
atttcagaaa atattatttc tctcttttta actactcttt ttttttatt tagacagagt 1560
cgcttgagcc caggaggttg aggttgagc gggccgagat tgtgccactg cactccaacc 1620
tggttgagag agtgagattc catctgaaaa acaaaaacaa aaacagaaaa caaacaacaa 1680
aaaaacaaaa aatccccaca actttgtcaa ataattgata ggcaaacact ttcaaatata 1740
atttcttca gtgaatacaa aatgttgata tcataggtga tgtacaattt agttttgaat 1800
gagttattat gttatcactg tgtctgatgt tatctacttt gaaaggcagt ccagaaaagt 1860
gttctaagtg aactcttaag atctatttta gataatttca actaattaaa taacctgttt 1920

```

```
tactgcctgt acattccaca ttaataaagc gataccaatc ttatatgaat gctaataatta 1980
ctaaaatgca ctgatatcac ttcttcttcc cctgttgaaa agctttctca tgatcatatt 2040
tcacccacat ctacacctga agaaacttac aggtagactt accttttcac ttgtggaatt 2100
aatcatatatt aaatcttact ttaaggctca ataaataata ctcataaaaa aaaaaaaaaa 2160
aaaaaa 2166
```

&lt;210&gt; 2

&lt;211&gt; 387

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```
Met Val Phe Ala Phe Trp Lys Val Phe Leu Ile Leu Ser Cys Leu Ala
  1           5           10           15

Gly Gln Val Ser Val Val Gln Val Thr Ile Pro Asp Gly Phe Val Asn
      20           25           30

Val Thr Val Gly Ser Asn Val Thr Leu Ile Cys Ile Tyr Thr Thr Thr
      35           40           45

Val Ala Ser Arg Glu Gln Leu Ser Ile Gln Trp Ser Phe Phe His Lys
      50           55           60

Lys Glu Met Glu Pro Ile Ser Ile Tyr Phe Ser Gln Gly Gly Gln Ala
      65           70           75           80

Val Ala Ile Gly Gln Phe Lys Asp Arg Ile Thr Gly Ser Asn Asp Pro
      85           90           95

Gly Asn Ala Ser Ile Thr Ile Ser His Met Gln Pro Ala Asp Ser Gly
      100          105          110

Ile Tyr Ile Cys Asp Val Asn Asn Pro Pro Asp Phe Leu Gly Gln Asn
      115          120          125

Gln Gly Ile Leu Asn Val Ser Val Leu Val Lys Pro Ser Lys Pro Leu
      130          135          140

Cys Ser Val Gln Gly Arg Pro Glu Thr Gly His Thr Ile Ser Leu Ser
      145          150          155          160

Cys Leu Ser Ala Leu Gly Thr Pro Ser Pro Val Tyr Tyr Trp His Lys
      165          170          175

Leu Glu Gly Arg Asp Ile Val Pro Val Lys Glu Asn Phe Asn Pro Thr
      180          185          190

Thr Gly Ile Leu Val Ile Gly Asn Leu Thr Asn Phe Glu Gln Gly Tyr
      195          200          205

Tyr Gln Cys Thr Ala Ile Asn Arg Leu Gly Asn Ser Ser Cys Glu Ile
      210          215          220

Asp Leu Thr Ser Ser His Pro Glu Val Gly Ile Ile Val Gly Ala Leu
      225          230          235          240

Ile Gly Ser Leu Val Gly Ala Ala Ile Ile Ile Ser Val Val Cys Phe
      245          250          255
```

Ala Arg Asn Lys Ala Lys Ala Lys Ala Lys Glu Arg Asn Ser Lys Thr  
 260 265 270

Ile Ala Glu Leu Glu Pro Met Thr Lys Ile Asn Pro Arg Gly Glu Ser  
 275 280 285

Glu Ala Met Pro Arg Glu Asp Ala Thr Gln Leu Glu Val Thr Leu Pro  
 290 295 300

Ser Ser Ile His Glu Thr Gly Pro Asp Thr Ile Gln Glu Pro Asp Tyr  
 305 310 315 320

Glu Pro Lys Pro Thr Gln Glu Pro Ala Pro Glu Pro Ala Pro Gly Ser  
 325 330 335

Glu Pro Met Ala Val Pro Asp Leu Asp Ile Glu Leu Glu Leu Glu Pro  
 340 345 350

Glu Thr Gln Ser Glu Leu Glu Pro Glu Pro Glu Pro Glu Pro Glu Ser  
 355 360 365

Glu Pro Gly Val Val Val Glu Pro Leu Ser Glu Asp Glu Lys Gly Val  
 370 375 380

Val Lys Ala  
 385

<210> 3

<211> 2946

<212> DNA

<213> Homo sapiens

<400> 3

tcgggctgcc ttatcgccaa gtccttcag gagaacaaag aacaggccat taccctggag 60  
 aagactggca actgatttta cccacaagcc caaacctcag ggatttcagt atctactagt 120  
 ctgggtagat actttcacgg gttgggcaga ggccttcccc ttaggacag aaaaggccca 180  
 agaggtaata aaggcactag ttcatagaat aattcccaga ttcggacttc cccaggcgtt 240  
 acagagtgc aatagccctg ctttcaggcc cacagtaacc caggaggtat cccaggcgtt 300  
 aggtatacga tatcacttac actgcgcctg aaggccacag tcctcaggga aggtcagaga 360  
 aatgaatgaa acactcaaag gacatctaaa aaagcaaacc caggaaaccc acctcacatg 420  
 gcctgctctg ttgcctatag ccttaaaaag aatctgcaac tttccccaaa aagcaggact 480  
 tagcccatat gaaatgctgt atggaagccc cttcataacc aatgaccttg tgcttgacct 540  
 aagacagcca acttagttgc agacatcacc tccttagcca aatatcaaca agttcttaaa 600  
 acattacaag gaacctatcc ctgagaagag ggaagaagac tattccaccc ttgtgacatg 660  
 gtattagtca agtcccttcc ctctaattcc ccatccctag atacatcctg ggaaggacct 720  
 taccagtcga ttttatctac cccaactgag gttaaagtgg ctggagtggg gtcttgata 780  
 catcacactt gagtcaaacc ctggatactg ccaaaggaaac ctgaaaatcc aggagacaac 840  
 gctagctatt cctgtgaacc tctagaggat ttgcgcctgc tcttcaaaca acaaccagga 900  
 ggaaagtaac taaaatcata aatcccatg gccctccctt atcatatttt tctctttact 960  
 gttcttttac cctctttcac tctactgca cccctccat gccgctgtat gaccagtagc 1020  
 tccccttacc aagagtttct atggagaatg cagcgtcccg gaaatattga tgccccatcg 1080  
 tataggagtc tttctaaggg aacccccacc ttcactgccc acacccatat gccccgcaac 1140  
 tgctatcact ctgccactct ttgcatgcat gcaaatactc attattggac aggaaaaatg 1200  
 attaatecta gttgtcctgg aggacttgga gtcactgtct gttggactta cttcacccaa 1260  
 actggtatgt ctgattgggg tgagattcaa gatcaggcaa gagaaaaaca tgtaaaagaa 1320  
 gtaattctccc aactcaccg ggtacatggc acctctagcc cctacaaagg actagatctc 1380  
 tcaaaaactac atgaaacct cctgacctat actgcctggt taagcctatt taataccacc 1440  
 ctactgggc tccatgaggt ctggcccaa aacctacta actgttggt atgcctccc 1500  
 ctgaacttca ggccatatgt ttcaatccct gtacctgaac aatggaacaa cttcagcaca 1560

```

gaaataaaca ccacttccgt tttagtagga cctcttgttt ccaatctgga aataacccat 1620
acctcaaacc tcacctgtgt aaaatttagc aatactacat acacaaccaa ctcccaatgc 1680
atcagggtggg taactcctcc cacacaaata gtctgcctac cctcaggaat attttttgtc 1740
tgtgttacct cagcctatcg ttgtttgaat ggctcttcag aatctatgtg cttcctctca 1800
ttcttagtgc cccctatgac catctacact gaacaagatt tatacaatta tgtcatatct 1860
aagccccgca acaaaaagagt acccattctt ccttttgtta taggagcagg agtgctaggt 1920
gcactaggta ctggcattgg cggatcacac acctctactc agttctacta caaactatct 1980
caagaactaa atggggacat ggaacggggt gccgactccc tggtcacctt gcaagatcaa 2040
cttaactccc tagcagcagt agtccttcaa aatcgaagag ctttagactt gctaaccgct 2100
gaaagagggg gaacctgttt atttttaggg gaagaatgct gttattatgt taatcaatcc 2160
ggaatcgta ctgagaaagt taaagaaatt cgagatcgaa tacaacgtag agcagaggag 2220
cttcgaaaca ctggaccctg gggcctcttc agccaatgga tgccctggat tctcccttc 2280
ttaggacctc tagcagctat aatattgcta ctctctttg gaccctgtat ctttaacctc 2340
cttgtaact ttgtctcttc cagaatcgaa gctgtaaaac tacaatgga gcccaagatg 2400
cagtcacaaga ctaagatcta ccgcagaccc ctggaccggc ctgctagccc acgatctgat 2460
gttaatgaca tcaaaggcac cctcctgag gaaatctcag ctgcacaacc tctactacgc 2520
cccaattcag caggaagcag ttagagcggg cgctgggcaa cctcccaac agcacttagg 2580
ttttcctgtt gagatgggg actgagagac aggactagct ggatttccta ggctgactaa 2640
gaatccctaa gcctagctgg gaaggtgacc acatccacct ttaaacacgg ggcttgcaac 2700
ttagctcaca cctgaccaat cagagagctc actaaaatgc taattaggca aaaacaggag 2760
gtaaagaaat agccaatcat ctattgcctg agagcacagc aggagggaca atgatcggga 2820
tataaaccca agtcttcgag ccggcaacgg caacccccct tgggtccctt ccctttgtat 2880
gggagctctg ttttcatgct atttactctt attaaatctt gcaactgcaa aaaaaaaaaa 2940
aaaaaa

```

&lt;210&gt; 4

&lt;211&gt; 538

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

Met Ala Leu Pro Tyr His Ile Phe Leu Phe Thr Val Leu Leu Pro Ser
  1              5              10              15

```

```

Phe Thr Leu Thr Ala Pro Pro Pro Cys Arg Cys Met Thr Ser Ser Ser
              20              25              30

```

```

Pro Tyr Gln Glu Phe Leu Trp Arg Met Gln Arg Pro Gly Asn Ile Asp
              35              40              45

```

```

Ala Pro Ser Tyr Arg Ser Leu Ser Lys Gly Thr Pro Thr Phe Thr Ala
  50              55              60

```

```

His Thr His Met Pro Arg Asn Cys Tyr His Ser Ala Thr Leu Cys Met
  65              70              75              80

```

```

His Ala Asn Thr His Tyr Trp Thr Gly Lys Met Ile Asn Pro Ser Cys
              85              90              95

```

```

Pro Gly Gly Leu Gly Val Thr Val Cys Trp Thr Tyr Phe Thr Gln Thr
              100              105              110

```

```

Gly Met Ser Asp Gly Gly Gly Val Gln Asp Gln Ala Arg Glu Lys His
              115              120              125

```

```

Val Lys Glu Val Ile Ser Gln Leu Thr Arg Val His Gly Thr Ser Ser
              130              135              140

```

```

Pro Tyr Lys Gly Leu Asp Leu Ser Lys Leu His Glu Thr Leu Arg Thr
              145              150              155              160

```

His Thr Arg Leu Val Ser Leu Phe Asn Thr Thr Leu Thr Gly Leu His  
 165 170 175  
 Glu Val Ser Ala Gln Asn Pro Thr Asn Cys Trp Ile Cys Leu Pro Leu  
 180 185 190  
 Asn Phe Arg Pro Tyr Val Ser Ile Pro Val Pro Glu Gln Trp Asn Asn  
 195 200 205  
 Phe Ser Thr Glu Ile Asn Thr Thr Ser Val Leu Val Gly Pro Leu Val  
 210 215 220  
 Ser Asn Leu Glu Ile Thr His Thr Ser Asn Leu Thr Cys Val Lys Phe  
 225 230 235 240  
 Ser Asn Thr Thr Tyr Thr Thr Asn Ser Gln Cys Ile Arg Trp Val Thr  
 245 250 255  
 Pro Pro Thr Gln Ile Val Cys Leu Pro Ser Gly Ile Phe Phe Val Cys  
 260 265 270  
 Gly Thr Ser Ala Tyr Arg Cys Leu Asn Gly Ser Ser Glu Ser Met Cys  
 275 280 285  
 Phe Leu Ser Phe Leu Val Pro Pro Met Thr Ile Tyr Thr Glu Gln Asp  
 290 295 300  
 Leu Tyr Asn Tyr Val Ile Ser Lys Pro Arg Asn Lys Arg Val Pro Ile  
 305 310 315 320  
 Leu Pro Phe Val Ile Gly Ala Gly Val Leu Gly Ala Leu Gly Thr Gly  
 325 330 335  
 Ile Gly Gly Ile Thr Thr Ser Thr Gln Phe Tyr Tyr Lys Leu Ser Gln  
 340 345 350  
 Glu Leu Asn Gly Asp Met Glu Arg Val Ala Asp Ser Leu Val Thr Leu  
 355 360 365  
 Gln Asp Gln Leu Asn Ser Leu Ala Ala Val Val Leu Gln Asn Arg Arg  
 370 375 380  
 Ala Leu Asp Leu Leu Thr Ala Glu Arg Gly Gly Thr Cys Leu Phe Leu  
 385 390 395 400  
 Gly Glu Glu Cys Cys Tyr Tyr Val Asn Gln Ser Gly Ile Val Thr Glu  
 405 410 415  
 Lys Val Lys Glu Ile Arg Asp Arg Ile Gln Arg Arg Ala Glu Glu Leu  
 420 425 430  
 Arg Asn Thr Gly Pro Trp Gly Leu Leu Ser Gln Trp Met Pro Trp Ile  
 435 440 445  
 Leu Pro Phe Leu Gly Pro Leu Ala Ala Ile Ile Leu Leu Leu Phe  
 450 455 460  
 Gly Pro Cys Ile Phe Asn Leu Leu Val Asn Phe Val Ser Ser Arg Ile  
 465 470 475 480

Glu Ala Val Lys Leu Gln Met Glu Pro Lys Met Gln Ser Lys Thr Lys  
                   485                                  490                                  495

Ile Tyr Arg Arg Pro Leu Asp Arg Pro Ala Ser Pro Arg Ser Asp Val  
                   500                                  505                                  510

Asn Asp Ile Lys Gly Thr Pro Pro Glu Glu Ile Ser Ala Ala Gln Pro  
                   515                                  520                                  525

Leu Leu Arg Pro Asn Ser Ala Gly Ser Ser  
                   530                                  535

<210> 5  
 <211> 338  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (259)

<220>  
 <221> unsure  
 <222> (261)

<220>  
 <221> unsure  
 <222> (282)

<220>  
 <221> unsure  
 <222> (285)

<220>  
 <221> unsure  
 <222> (312)

<220>  
 <221> unsure  
 <222> (334)

<400> 5  
 agcggccgcg ccattcccat caagcagggg atcctgctaa agcggagcgg caagtccttg 60  
 aacaaggagt ggaagaagaa gtatgtgacg ctctgtgaca acgggctgct cacctatcac 120  
 ccagcctgc atcttggtgc gctgtctgtg cctctgcca acagtggagg cagcgaggat 180  
 gaagaggagt ggcaaggggt gtcttgatg tggaaaaaaaa tgtgggttgt ggggttgggc 240  
 tgggttttgg ttctagtana ngaaacacag ccagctggag ancanaactc acgggggttg 300  
 gtggcttttc anaatcaccg ggctgggtgc tganctaa 338

<210> 6  
 <211> 387  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (30)

<220>  
 <221> unsure  
 <222> (163)

<400> 6  
 aagtaggcaa gggataataa ccaaagaagn aaatttcatg aagactagac atcataaagc 60  
 ataattttta tagtcaactca accaagtatt ttttattttt tatggatact ctgaatggca 120  
 attaaatgtg aaacccagtt tcttgggcaa gtcaaattst ggnatcacat ccacctaaat 180  
 taaaatgact agctcggtatt ttcccatct tcaagtttca catcctgggc atcaaaagac 240  
 tcgacagcaa gacttagaat gmaaaagggt acttggttat attaataattt ttacttgaa 300  
 cagtgtagc ttgcagcagg ttcttgatga atgtgcttg tgtccaaaat gcctcccat 360  
 tgtacacagg tgtacacat gcatgca 387

<210> 7  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> UNSURE  
 <222> (26)

<400> 7  
 Met Thr Ser Ser Tyr Phe Pro His Leu Gln Val Ser His Pro Gly His  
 1 5 10 15  
 Gln Lys Thr Arg Gln Gln Asp Leu Glu Xaa Lys Arg Val Leu Val Tyr  
 20 25 30  
 Ile Asn Ile Phe Tyr Leu Asn Thr Cys Ser Leu Gln Gln Val Leu Asp  
 35 40 45  
 Glu Cys Ala Leu Cys Pro Lys Cys Leu Pro Ile Val His Arg Cys Thr  
 50 55 60  
 Pro Cys Met  
 65

<210> 8  
 <211> 348  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (59)

<220>  
 <221> unsure  
 <222> (70)

<220>  
 <221> unsure  
 <222> (72)

<220>  
 <221> unsure  
 <222> (87)



<220>  
 <221> unsure  
 <222> (89)

<220>  
 <221> unsure  
 <222> (92)

<220>  
 <221> unsure  
 <222> (94)

<220>  
 <221> unsure  
 <222> (134)

<220>  
 <221> unsure  
 <222> (138)

<220>  
 <221> unsure  
 <222> (202)

<220>  
 <221> unsure  
 <222> (216)

<220>  
 <221> unsure  
 <222> (223)

<220>  
 <221> unsure  
 <222> (303)

<400> 8  
 caaacccctaa accctggcag gaagcatgtc gaggaaggag ttccggcaac tccagaggnt 60  
 ccgacagaan tntgggctga gcctggntnt cntntccagc aagggtttcg cctgagcccc 120  
 aagggcatcg ggantggnga ctcacctatg gatgggggcc ggggagacag gacacacaga 180  
 agatgagttt gtggggccagc cntgagcccc gcgccngatt ttngccggcc caagagagcc 240  
 cgccgcagct tccccattt tgcagccagc ggagccattc acacaatcac cttctgttaa 300  
 ttntatctgc aacatcaatt aaattgtttg tagaaactaa aaaaaaaaa 348

<210> 9  
 <211> 3153  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 taatcatgcc tcttggaggt aagttaacgg gcgtgattgt ggaaaatgar aatattacca 60  
 aagaaggtgg cttaktggac atggccaaga aagaaaatga cttaaattgca gagcccaatt 120  
 taaagcagac aattaaagca acagtagara atggcaagaa ggatggcatt gctgttgatc 180  
 atgttgtagg cctgaataca gaaaaatatg ctgaaactgt cmaacttaag cataaaagaa 240  
 scccaggtaa agtaaaagac atwtcmattg atgttgaaag aaggaatgaa aacagtgagg 300  
 tagacaccag tgctggaagt ggctctgcac cctctgtttt acaccaaagg aacggacaaa 360  
 ctgaggatgt ggcaactggg cctaggagag cagaaaagac ttctgttgcc actagtactg 420  
 aagggaagga caaagatgtc accttaagtc cagtgaaggc tgggcctgcc acaaccactt 480  
 cttcagaaac aagacaaagt gaggtggctt tgccttgac cagcattgag gcagatgaag 540  
 gcctcataat aggaacacat tccagaaata atcctcttca tggttggtgca gaagccagtg 600

```

aatgcactgt ttttctgtgca gctgaaaaag gtggggctgt tgtcacagag ggatttgctg 660
aaagtgaac ctctctcaca agcactaagg aaggggaaag tggggagtgt gctgtggctg 720
aatctgagga cagagcagca gacctactgg ctgtgcatgc agttaaaatc gaagccaatg 780
taaatacgct tgtgacagag gaaaaggatg atgctgtaac cagtgcaggc tctgaagaaa 840
aatgtgatgg ttctttaagt agagactcag aaatagttga aggaactatt acttttatta 900
gtgaagttga aagtgtatgga gcagttacaa gtgctggaac agagataaga gcaggatcta 960
taagcagtga agaggtggat ggctcccagg gaaatatgat gagaatgggt cccaaaaaag 1020
aaacagaggg cactgtgaca tgtacaggag cagaaggcag aagtgataac tttgtgatct 1080
gctcagtaac tggagcaggg ccccgggagg aacgcattgt tacagggtgca ggtgtgtgctc 1140
tgggagataa tgaatgcacca ccaggaacaa gtgccagcca agaaggagat ggttctgtga 1200
atgatgggtac agaaggtgag agtgcagtca ccagcacggg gataacagaa gatggagagg 1260
ggccagcaag ttgcacaggt tcagaagatw gcakcgaagg ctttgctata agttctgaat 1320
cggaagaaaa tggagagagt gcaatggaca gcacagtggc caaagaaggc actaatgtac 1380
cattagttgc tgcctggctcct tgtgatgatg aaggcattgt gactagcaca ggcgcaaaag 1440
aggaagacga ggaaggggag gatgttgtga ctagtactgg aagaggaaat gaaattgggc 1500
atgcttcaac ttgtacaggg ttaggagaag aaagtgaagg ggtcttgatt tgtgaaagtg 1560
cagaagggga cagtgcagatt ggtactgtgg tagagcatgt ggaagctgag gctggagctg 1620
ccatcatgaa tgcaaatgaa aataatgttg acagcatgag tggcacagag aaaggaagta 1680
aagacacaga tatctgctcc agtgcmaaag ggattgtaga aagcagtgtg accagtgcag 1740
tctcaggaaa ggatgaagtg acaccagttc caggaggttg tgagggtcct atgactagtg 1800
ctgcatctga tcaaagtgaac agtcagctcg aaaaagtgtg agataccact atttccactg 1860
gcctggctcg gggtagttac gatgttcttg tatctgggtg agtcccagaa tgtgaagttg 1920
ctcacacatc accaagtga aagaagatg aggacatcat cacctctgta gaaaatgaag 1980
agtgtgatgg tttcatggca actacagcca gtggtgatat taccaaccag aatagcttag 2040
cagggggtaa aaatcaaggc aaagttttga ttatttccac cagtaccaca aatgattaca 2100
cccctcaggt aagcgcaatt acagatgtgg aaggaggtct ttcagatgct ctgagaactg 2160
aagaaaatat ggaagggtacc agagtaacca cagaagaatt tgaggccccc atgcccagtg 2220
cagtctcagg agatgacagc caactcactg ccagcagaag tgaagagaaa gatgagtgtg 2280
ccatgatattc cacaagcata ggggaagaat tcgaattgcc tatctccagt gcaacaacca 2340
tcaagtgtgc tgaaagtttc agccggttgc tgcagcagtg gaagaaaggg ctacagggtcc 2400
agtcttgata agcaccgccg actttgaggg gcctatgccc agtgcgcccc cagaagctga 2460
aagtctcttt gcctcaacca gcaaggagga gaaggatgaa tgtgctctca tttccactag 2520
catagcgaga gaatgtgagg cttctgtttc cgggtgtagt gttgaaagtg aaaatgagcg 2580
agctggcaca tcatggaag aaaaagacgg gagtggcatc atctttacga gctcggtgga 2640
agactgtgag ggcccagtg ccagtgtgtt ccctcaagag gaaggcgacc cctcagtcac 2700
accagcggaa gagatgggtg acaccgccat gatttccaca agcacctctg aagggtgtga 2760
agcagtcatg attggtgctg tcctccagga tgaagatcgg ctaccatca caagagtaga 2820
agacttgagc gatgctgcca tcatctccac cagcacagca gaatgtatgc caatttccgc 2880
cagcattgac agacatgaag agaatcagct gactgcagac aaccagaaag ggaacggtga 2940
cytgtcagcc acagaagtga gcaagcacia gktccccatg cccagcytaa ttgctgagaa 3000
taactgtcgg tgtcctgggc cagtcagggg aggcacaaga ctgggtcccc tgttggcagt 3060
gagcaccgag gaggggcaca acgggccatc agtcacaaag ccctctgcag ggcaaggcca 3120
tcaagtgtctg tttgtgcgga aaaaaaaaaa aaa 3153

```

&lt;210&gt; 10

&lt;211&gt; 800

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (24)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (73)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (79)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (429)..(430)

&lt;400&gt; 10

```

Met Pro Leu Gly Ser Lys Leu Thr Gly Val Ile Val Glu Asn Glu Asn
  1              5              10              15

Ile Thr Lys Glu Gly Gly Leu Xaa Asp Met Ala Lys Lys Glu Asn Asp
      20              25              30

Leu Asn Ala Glu Pro Asn Leu Lys Gln Thr Ile Lys Ala Thr Val Glu
      35              40              45

Asn Gly Lys Lys Asp Gly Ile Ala Val Asp His Val Val Gly Leu Asn
      50              55              60

Thr Glu Lys Tyr Ala Glu Thr Val Xaa Leu Lys His Lys Arg Xaa Pro
      65              70              75              80

Gly Lys Val Lys Asp Ile Ser Ile Asp Val Glu Arg Arg Asn Glu Asn
      85              90              95

Ser Glu Val Asp Thr Ser Ala Gly Ser Gly Ser Ala Pro Ser Val Leu
      100             105             110

His Gln Arg Asn Gly Gln Thr Glu Asp Val Ala Thr Gly Pro Arg Arg
      115             120             125

Ala Glu Lys Thr Ser Val Ala Thr Ser Thr Glu Gly Lys Asp Lys Asp
      130             135             140

Val Thr Leu Ser Pro Val Lys Ala Gly Pro Ala Thr Thr Thr Ser Ser
      145             150             155             160

Glu Thr Arg Gln Ser Glu Val Ala Leu Pro Cys Thr Ser Ile Glu Ala
      165             170             175

Asp Glu Gly Leu Ile Ile Gly Thr His Ser Arg Asn Asn Pro Leu His
      180             185             190

Val Gly Ala Glu Ala Ser Glu Cys Thr Val Phe Ala Ala Ala Glu Lys
      195             200             205

Gly Gly Ala Val Val Thr Glu Gly Phe Ala Glu Ser Glu Thr Phe Leu
      210             215             220

Thr Ser Thr Lys Glu Gly Glu Ser Gly Glu Cys Ala Val Ala Glu Ser
      225             230             235             240

Glu Asp Arg Ala Ala Asp Leu Leu Ala Val His Ala Val Lys Ile Glu
      245             250             255

Ala Asn Val Asn Ser Val Val Thr Glu Glu Lys Asp Asp Ala Val Thr
      260             265             270

Ser Ala Gly Ser Glu Glu Lys Cys Asp Gly Ser Leu Ser Arg Asp Ser
      275             280             285

```

Glu Ile Val Glu Gly Thr Ile Thr Phe Ile Ser Glu Val Glu Ser Asp  
 290 295 300  
 Gly Ala Val Thr Ser Ala Gly Thr Glu Ile Arg Ala Gly Ser Ile Ser  
 305 310 315 320  
 Ser Glu Glu Val Asp Gly Ser Gln Gly Asn Met Met Arg Met Gly Pro  
 325 330 335  
 Lys Lys Glu Thr Glu Gly Thr Val Thr Cys Thr Gly Ala Glu Gly Arg  
 340 345 350  
 Ser Asp Asn Phe Val Ile Cys Ser Val Thr Gly Ala Gly Pro Arg Glu  
 355 360 365  
 Glu Arg Met Val Thr Gly Ala Gly Val Val Leu Gly Asp Asn Asp Ala  
 370 375 380  
 Pro Pro Gly Thr Ser Ala Ser Gln Glu Gly Asp Gly Ser Val Asn Asp  
 385 390 395 400  
 Gly Thr Glu Gly Glu Ser Ala Val Thr Ser Thr Gly Ile Thr Glu Asp  
 405 410 415  
 Gly Glu Gly Pro Ala Ser Cys Thr Gly Ser Glu Asp Xaa Xaa Glu Gly  
 420 425 430  
 Phe Ala Ile Ser Ser Glu Ser Glu Glu Asn Gly Glu Ser Ala Met Asp  
 435 440 445  
 Ser Thr Val Ala Lys Glu Gly Thr Asn Val Pro Leu Val Ala Ala Gly  
 450 455 460  
 Pro Cys Asp Asp Glu Gly Ile Val Thr Ser Thr Gly Ala Lys Glu Glu  
 465 470 475 480  
 Asp Glu Glu Gly Glu Asp Val Val Thr Ser Thr Gly Arg Gly Asn Glu  
 485 490 495  
 Ile Gly His Ala Ser Thr Cys Thr Gly Leu Gly Glu Glu Ser Glu Gly  
 500 505 510  
 Val Leu Ile Cys Glu Ser Ala Glu Gly Asp Ser Gln Ile Gly Thr Val  
 515 520 525  
 Val Glu His Val Glu Ala Glu Ala Gly Ala Ala Ile Met Asn Ala Asn  
 530 535 540  
 Glu Asn Asn Val Asp Ser Met Ser Gly Thr Glu Lys Gly Ser Lys Asp  
 545 550 555 560  
 Thr Asp Ile Cys Ser Ser Ala Lys Gly Ile Val Glu Ser Ser Val Thr  
 565 570 575  
 Ser Ala Val Ser Gly Lys Asp Glu Val Thr Pro Val Pro Gly Gly Cys  
 580 585 590  
 Glu Gly Pro Met Thr Ser Ala Ala Ser Asp Gln Ser Asp Ser Gln Leu  
 595 600 605

Glu Lys Val Glu Asp Thr Thr Ile Ser Thr Gly Leu Val Gly Gly Ser  
 610 615 620  
 Tyr Asp Val Leu Val Ser Gly Glu Val Pro Glu Cys Glu Val Ala His  
 625 630 635 640  
 Thr Ser Pro Ser Glu Lys Glu Asp Glu Asp Ile Ile Thr Ser Val Glu  
 645 650 655  
 Asn Glu Glu Cys Asp Gly Phe Met Ala Thr Thr Ala Ser Gly Asp Ile  
 660 665 670  
 Thr Asn Gln Asn Ser Leu Ala Gly Gly Lys Asn Gln Gly Lys Val Leu  
 675 680 685  
 Ile Ile Ser Thr Ser Thr Thr Asn Asp Tyr Thr Pro Gln Val Ser Ala  
 690 695 700  
 Ile Thr Asp Val Glu Gly Gly Leu Ser Asp Ala Leu Arg Thr Glu Glu  
 705 710 715 720  
 Asn Met Glu Gly Thr Arg Val Thr Thr Glu Glu Phe Glu Ala Pro Met  
 725 730 735  
 Pro Ser Ala Val Ser Gly Asp Asp Ser Gln Leu Thr Ala Ser Arg Ser  
 740 745 750  
 Glu Glu Lys Asp Glu Cys Ala Met Ile Ser Thr Ser Ile Gly Glu Glu  
 755 760 765  
 Phe Glu Leu Pro Ile Ser Ser Ala Thr Thr Ile Lys Cys Ala Glu Ser  
 770 775 780  
 Phe Ser Arg Leu Leu Gln Gln Trp Lys Lys Gly Leu Gln Val Gln Ser  
 785 790 795 800

&lt;210&gt; 11

&lt;211&gt; 2426

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

tctgttcccc agctggagct gcgttggggac ccgtcgggac gtaaatccca tgtaaggtat 60  
 ctgccgtcgg aagatttgaa ctttctaatt ggacacctaa caccacagct cctccagggtg 120  
 ggctcctaagg atcttaggag caacgatggg gggtcctaag ccaggggggg atgagggtct 180  
 ggctctcagt ccccgctcg cggggagtg cccccctc tgcgatgggg gtcctaagag 240  
 ccagtggggg aaccaggggc tggctctcag tccctgcctc gcgggggggtg cctccccccc 300  
 tgtgatgggg gtactaacag ccaggggagg aagaggggat agctctcagt cccaccttc 360  
 gcgggggggtg cctccccctc gtgcgatggg gggtcctaaga tccagggggg gaagaggggac 420  
 tggctctcag tccctgcctc gcgggggggtg cctccccccc tgcgatgggg gtactcacag 480  
 ccaggggtgg aagaggggat agctctcagt cccactctc gtgggggggtg cctccccctc 540  
 ctgcgatggg ggtcctcaga gccggggggg aagaggggtc ggctctcagt aatcccacgt 600  
 aagggtacct ctgtcggaag atttgaactt tctacttgga caactaacac ccacagtcc 660  
 ccaggtgggt cctaaggatc ttaggatcaa tgatgggggg tcctaagccg gtggggggaag 720  
 aggggtctgc tctcagtcgc cgcctcgcgg ggggtgcctc cccctctgc gatgggggtc 780  
 ctaagagcca gtggggggaac caggggctgg ctctcaatcc ctgcctcgcg ggggttactc 840  
 cccctctcgt cgatgggggt accaacagcc aggggaggaa gaggggatag ctctcagtc 900  
 ccacccctcg ggggttgct cccctctcgt cgatgggggt cctaagatcc tggggaggaa 960  
 gagggactgg ctctcagtaa tcccacctaa ggtacctgcc gtcggaagat ttgaactttc 1020

```

tacttggaca actaacaccc acagtccctcc aggtgggtcc taaggatcctt aggatcaatg 1080
atgggggggtc ctaagccagg ggggaagagg gtctggcact cagtccctgc ctgcgggggg 1140
gtgcctccgc cccagcgat gggggtccta agagcaaagg ggggaagagg ggctccctct 1200
cagtccccgc gtgcgaggg gtgcctcccc ccctgcgatg gcggtgcaaa gagccagggg 1260
aggaaagagg gaggttcgca gtccccgcct cgcggaatt gcctcccccc ctgctatggt 1320
gggtcccaaga gccagggggg gaagaggggt tggctctgag tccccgcctc gcgggggggtg 1380
cctccccccc tgcgatggga gtcccaagag ccagggggta agaggggatg gatctcagcc 1440
atcacaaaat ggggggcctt tatgttcagg ttttacccaa gaatcagctt atttgcttct 1500
tgtactagca gggcagttgc tgccaaggcc ctcaaatagg ggggccatcc tttagcaacc 1560
ctgtctagtt gtttagagac gtaggctacg ggcctcagcc agggccccac agtttggggt 1620
aaaagtcag ctgccatctt ttctctctct gacgcataca atggaaaagg ctttgtcagg 1680
tcgggtgggc tgccagaaga ttttcttgta actcatgaaa aacttgctgt tgttgggatc 1740
cccatattcaa agttccggg tccccgcccc atttgtagc tcatacaaag gcttggtctaa 1800
tactgcagtt tgggatccac agcctacaaa accccacagc tctaagaat tctctcacct 1860
gccttctgcc cttaagctcc ggtagattgc aaataacctg ctttcttctt gttcccagc 1920
tgtgttcgga cccgtcggat cgtaaatccc acgtaaggtc ggaagatttg aactttctac 1980
ttggacacct aacaccaca gtccctcagg tacctgccgt cggaagattt gaacgttcta 2040
cttggacaac taacaccac agtcctccag acagaaagac aacaggtaca aagccctaag 2100
gattataaag gtatgctgct taccatcatc ttagtgacca aggcagcgaa gctgtttctg 2160
taccttggaa cagtcttccc tgacaagcca gagaacagt ataaagccac cagccttggg 2220
atcaggactg aaaaggcaag agtgatggag atttctctg cgctaagcca agagaagggt 2280
tcagcacttc agacagctcc caccgaagta gccgcgctcc cagctgcttg cagatgttga 2340
aaaggaaagc ctcggtttgt cttgaggttg tcagcaggtg caagacacgt aataaaatgc 2400
aatgtgttcc taaaaaaaa aaaaaa 2426

```

&lt;210&gt; 12

&lt;211&gt; 75

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

```

Met Leu Leu Thr Ile Ile Leu Val Thr Lys Ala Ala Lys Leu Phe Leu
  1             5             10             15

```

```

Tyr Leu Gly Thr Val Phe Pro Asp Lys Pro Glu Asn Ser Asp Lys Ala
      20             25             30

```

```

Thr Ser Leu Gly Ile Arg Thr Glu Lys Ala Arg Val Met Glu Ile Ser
      35             40             45

```

```

Pro Ala Leu Ser Gln Glu Lys Val Ser Ala Leu Gln Thr Ala Pro Thr
      50             55             60

```

```

Glu Val Ala Ala Leu Pro Ala Ala Cys Arg Cys
      65             70             75

```

&lt;210&gt; 13

&lt;211&gt; 429

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (10)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (18)..(19)

<220>  
 <221> unsure  
 <222> (24)

<220>  
 <221> unsure  
 <222> (97)

<220>  
 <221> unsure  
 <222> (117)

<220>  
 <221> unsure  
 <222> (142)..(143)

<400> 13  
 cttggtccan ttggtttntt tcgnttcccc cttttttctt cccttggttt tctttttttt 60  
 cgggcaacaa tatatttccaa ggctaataacc aaggcanacc aattcaactc ccaaggntcg 120  
 ggaatttttta acctttttaat tnnatggccc ctccactcc ttttctacgg cgatttgtct 180  
 gtgtctggcc cccacccact gcccatcccc cattgtgtgc tggatgtggt tctatttttt 240  
 atcgggtctcc tttccctccc tccccgttct cgcccccgcc ccacccctg ctccactac 300  
 cctttgtctc ttgtctcttc ttgggcttct gtacaactca acttgtatac actgtgtaca 360  
 cacaaccagc caaacgaaaa cccaacggcr aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 420  
 aaaaaaaaaa 429

<210> 14  
 <211> 130  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> UNSURE  
 <222> (4)

<220>  
 <221> UNSURE  
 <222> (6)..(7)

<220>  
 <221> UNSURE  
 <222> (33)

<220>  
 <221> UNSURE  
 <222> (48)

<400> 14  
 Leu Gly Pro Xaa Gly Xaa Xaa Arg Phe Pro Leu Phe Leu Pro Leu Gly  
 1 5 10 15  
 Phe Leu Phe Phe Arg Ala Thr Ile Phe Ser Lys Ala Asn Thr Lys Ala  
 20 25 30  
 Xaa Gln Phe Asn Ser Gln Gly Ser Gly Ile Phe Asn Leu Leu Ile Xaa  
 35 40 45  
 Trp Pro Leu Pro Leu Leu Phe Tyr Gly Asp Leu Ser Val Ser Gly Pro  
 50 55 60

His Pro Leu Pro Ile Pro His Cys Cys Leu Asp Val Val Leu Phe Phe  
65 75 80

Ile Gly Leu Leu Ser Pro Pro Pro Arg Ser Arg Pro Arg Pro Thr Pro  
85 90 95

Cys Ser His Tyr Pro Leu Ser Leu Ala Leu Ser Trp Ala Ser Val Gln  
100 105 110

Leu Asn Leu Tyr Thr Leu Cys Thr His Asn Gln Pro Asn Glu Asn Pro  
115 120 125

Thr Ala  
130

<210> 15  
<211> 271  
<212> DNA  
<213> Homo sapiens

<400> 15  
gcccccttcca cctctttctcc tatgacttkg aggactcctc cctgtccacc aaggagaagg 60  
aagcagagtc ccagaaggaa aacagatata gcaatttttg caataactct tatcactcct 120  
caagaccctc atctggatcc agtgtgcccc ccacccccac atcatccgtc tcacccccac 180  
aggaggccag gttggaaagg tcatcaccga gtggtcttct cacatcatcc ttcaggcagc 240  
accaagagtc actggcaaaa aaaaaaaaaa a 271

<210> 16  
<211> 38  
<212> PRT  
<213> Homo sapiens

<400> 16  
Val Pro Thr Thr Pro Thr Ser Ser Val Ser Pro Pro Gln Glu Ala Arg  
1 5 10 15

Leu Glu Arg Ser Ser Pro Ser Gly Leu Leu Thr Ser Ser Phe Arg Gln  
20 25 30

His Gln Glu Ser Leu Ala  
35

<210> 17  
<211> 1630  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (1622)

<400> 17  
cctgacctca ggtgatctgc ccgcctcggc ctctgaaagt gctgggatta taggcatgag 60  
ccaacatgcc tgacctgtta tttattttta attatatcag gaatacacac acacacacac 120  
acacacacac acacacacac acaacttata aagataatgg tctccttggc actcccaccc 180  
accaccccat ccaaatttac acaagtaaat ctgtaatcaa tttgggttaga agggatttat 240  
tttaatatat tttggggattg cttatgatgc agtataattt ttagttatat tagtagtaat 300  
tggaatgtg tattttttgtg actgaagtca ccttctaaat aatttctaga ataaaatttt 360



```

tatattgaag aagttggtct taaccatttt tttttcagga gcatgcattt tgaaatcatt 420
ctgtggggaag atgaaaacaa atttagttct atgtctcccc tttttagaga tgttgacact 480
ttccttaaat gtaccatgca tgatttgtct accacccttt tagcttgta tacttaaatc 540
ccagatctct gtcttcccat ttcagtttct ctagaatttc tggctgcttc caatgggtca 600
aatttatgag tgaaccatta agaatcactt agtgtagaaa taaaccatgg gttaggagtt 660
tgaacactgc ctaggttctg tttctgattt gattatgact cagctgtgtg gccttgggaa 720
accaccttac tggtatccct atccttgag aagcaagaga gttaatgatg gttgacttaa 780
tctcttgtgg ttattatgaa gatcagataa gatacattaa cacattttgc caactgaatt 840
aggttatatta ttacatgtg tgtccatgga cctggggatc aggtgctatg tctcagcctt 900
atcctttgtt ttaatcctgt gtctctaatt gtgtttgtca gtaaaggagt gagtcattta 960
atggttgcta gatgtttgag taaaacaaac aagcaaaaca atggttaaatt agtactattt 1020
ctttttaaaa aatttttttt tacattttta aaattataga taaatacaga gatgaggtct 1080
caccatgttg ccagctctgg tttcaaatc ctaaaactca gtgacctct ctcctcagcc 1140
tcccaaagtg ctaggattac aggcgtgagc caccatgcct ggccagtagt actattttct 1200
tgggaaaata ttagtagta gtcaacaaag ttgagcatac tgtgacctgg cagttttgat 1260
gctaagtawa taccacacag aaatgcaaac atatacttac caaaactcat gtccaagaat 1320
attcgtagaa gcacaattct tatgatagca aaaaggtaga aaacaacyta aatgttitya 1380
agcagtagca taagagtaat accgtgtggt ttgtttatac agtgagatcc tgtacagcca 1440
tgtaaaagac caaaatattc cctgtaacaa tgagaatgaa tctcctgtgc ttgcttcggc 1500
agcacatata ctaaaatttg aacgatacag agattagcat ggcccctgtg caaggagaat 1560
gaatyttcgt aatgttcagc aaaagaagcc agatataaat gaatattcca ttttataaaa 1620
anaaaaaaaaaa 1630

```

&lt;210&gt; 18

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

```

Met Lys Thr Asn Leu Val Leu Cys Leu Pro Phe Leu Glu Met Leu Thr
  1              5              10              15

```

```

Leu Ser Leu Asn Val Pro Cys Met Ile Cys Leu Pro Pro Phe
      20              25              30

```

&lt;210&gt; 19

&lt;211&gt; 456

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

```

aagaaggaga ctgtaagctt gtttgtacaa aaacatacca tacagagaaa gctgaagaca 60
aacaaaagtt agaattcttg aaaaaaagca tgttattgaa ttatcaacat cactggattg 120
tggaataat gctgtaacg ttggtgttacg atgttgaaaga tggtcagggt ctgtaatcct 180
ggatttccta ttggctgtta cattacagat aaaggccatg caaaagatgc ctgtgttatt 240
agttcagatt tccatgaaag agatacattt tacatcttca accatgttga catcaaaaata 300
tactatcatg ttgttgaaac tgggtccatg ggagcaagat tagtggctgc taaacttgaa 360
ccgaaaagct tcaaacatac ccatatagat aaaccagact gctcagggcc ccccatggac 420
ataagtaaca aggccttctg ggagataaaa attgca 456

```

&lt;210&gt; 20

&lt;211&gt; 519

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (4)

<220>  
<221> unsure  
<222> (12)

<220>  
<221> unsure  
<222> (28)

<220>  
<221> unsure  
<222> (35) .. (36)

<220>  
<221> unsure  
<222> (51)

<220>  
<221> unsure  
<222> (63) .. (65)

<220>  
<221> unsure  
<222> (90)

<220>  
<221> unsure  
<222> (111) .. (112)

<220>  
<221> unsure  
<222> (123)

<220>  
<221> unsure  
<222> (136)

<220>  
<221> unsure  
<222> (148)

<220>  
<221> unsure  
<222> (157)

<220>  
<221> unsure  
<222> (161)

<220>  
<221> unsure  
<222> (204)

<220>  
<221> unsure  
<222> (239)

<220>  
<221> unsure  
<222> (305)

<400> 20  
 caantaataa anctttttgtt tccctcgnc a ttgtnttcgt tccctgtcc ngccttgttt 60  
 cennngtcct gcaccaatat ttccaaaccn aatacccaag catacaatcc nnactccaag 120  
 ctnggaattc gcccanagag accgtcgngg gaagaantt nctggaaact tgttcattggt 180  
 gatataacc gtccctccaag aaangggatg ctgctatcag tctttctagg agccgggana 240  
 cagatattaa ttatgacctt tgtgactcta tttttcgctt gcctgggagt tttgtcacct 300  
 cccanccgag gagcgctgat gacgtgtgct gtggctcctgt ggggtgctgct gggcacccct 360  
 gcaggctatg tttctgccag attctataag tcctttggag gtgagaagt gaaaacaaat 420  
 gttttattaa catcatttct ttgtcctggg attgtatttg ctgacttctt tataatgaat 480  
 ctgatcctct ggtcaacggc ctctttggcc ctcgagaca 519

<210> 21  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> UNSURE  
 <222> (18)

<400> 21  
 Met Thr Phe Val Thr Leu Phe Phe Ala Cys Leu Gly Val Leu Ser Pro  
 1 5 10 15  
 Pro Xaa Arg Gly Ala Leu Met Thr Cys Ala Val Val Leu Trp Val Leu  
 20 25 30  
 Leu Gly Thr Pro Ala Gly Tyr Val Ser Ala Arg Phe Tyr Lys Ser Phe  
 35 40 45  
 Gly Gly Glu Lys Trp Lys Thr Asn Val Leu Leu Thr Ser Phe Leu Cys  
 50 55 60  
 Pro Gly Ile Val Phe Ala Asp Phe Phe Ile Met Asn Leu Ile Leu Trp  
 65 70 75 80  
 Ser Thr Ala Ser Leu Ala Leu Glu Thr  
 85

<210> 22  
 <211> 507  
 <212> DNA  
 <213> Homo sapiens

<400> 22  
 ttctttcccat acacctttcc cccataagat gtgtcttcaa cactataaag catttgattt 60  
 gtgatttgat taagtatata tttgggttgt ctcaatgaag agcaaattta aatattatgt 120  
 gcatttgtaa atacagtagc tataaaattt tccatacttc taatggcaga atagaggagg 180  
 ccatattaaa taatactgat gaaaggcagg aactgcatt gtaaatagga ttttctaggc 240  
 tcggtaggca gaaagaatta tttttctttg aaggaaataa ctttttatca tggtaatttt 300  
 gaaggatgat tcctatgatg tggtcaccag gggaaatgtg cttttaaaga aaatcttcta 360  
 ttggttgtaa ctgttcatat cttcttactt tctgtgttg acttcattat tcccatggta 420  
 ttggcctttt aaactatgtg cctctgagtc tttcaattta taaatttgta tcttaataaa 480  
 tattataaaa atgaaaaaaa aaaaaaa 507

<210> 23  
 <211> 622  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (32)

<220>  
 <221> unsure  
 <222> (57)

<220>  
 <221> unsure  
 <222> (66)

<220>  
 <221> unsure  
 <222> (72)

<220>  
 <221> unsure  
 <222> (105)

<400> 23  
 gggtctctcgg gacacccgtg gatggacacg gnaaggaaac accaggccaa ccacagntgg 60  
 ggatanaata gnacaaccac accctgccgt ccagagcctc ccagnctgtg ccccgtocta 120  
 gtaccaccag caaccatcaa tcccgtctcc tctgcctcc tctcctgcaa tccacccgc 180  
 cacgactatc gccatggcag ccctgatcgc agagaacttc cgcttctgt cacttttctt 240  
 caagagcaag gatgtgatga ttttcaacgg cctgggtggca ctgggcacgg tgggcagcca 300  
 ggagctgttc tctgtggtgg ccttccactg cccctgctcg ccggcccgga actacctgta 360  
 cgggctggcg gccatcgcg tggccgccct ggtgctcttc atcattggca tcaccccaa 420  
 caaccacacc tggaacctcg tggccgagtg ccagcaccgg aggaccaaga actgctccgc 480  
 cgccccacc ttctctcttc taagctccat cctgggacgt gcggctgtgg cccctgtcac 540  
 ctggtctgtc atctccctgc tgcgtggtga ggcttatgtc tgtgctctca gtgagttcgt 600  
 ggacccttcc tcactcacgg cc 622

<210> 24  
 <211> 143  
 <212> PRT  
 <213> Homo sapiens

<400> 24  
 Met Ala Ala Leu Ile Ala Glu Asn Phe Arg Phe Leu Ser Leu Phe Phe  
 1 5 10 15  
 Lys Ser Lys Asp Val Met Ile Phe Asn Gly Leu Val Ala Leu Gly Thr  
 20 25 30  
 Val Gly Ser Gln Glu Leu Phe Ser Val Val Ala Phe His Cys Pro Cys  
 35 40 45  
 Ser Pro Ala Arg Asn Tyr Leu Tyr Gly Leu Ala Ala Ile Gly Val Pro  
 50 55 60  
 Ala Leu Val Leu Phe Ile Ile Gly Ile Ile Leu Asn Asn His Thr Trp  
 65 70 75 80  
 Asn Leu Val Ala Glu Cys Gln His Arg Arg Thr Lys Asn Cys Ser Ala  
 85 90 95  
 Ala Pro Thr Phe Leu Leu Leu Ser Ser Ile Leu Gly Arg Ala Ala Val  
 100 105 110

Ala Pro Val Thr Trp Ser Val Ile Ser Leu Leu Arg Gly Glu Ala Tyr  
115 120 125

Val Cys Ala Leu Ser Glu Phe Val Asp Pro Ser Ser Leu Thr Ala  
130 135 140

<210> 25  
<211> 314  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (38)

<220>  
<221> unsure  
<222> (50)

<220>  
<221> unsure  
<222> (58)

<220>  
<221> unsure  
<222> (63)

<220>  
<221> unsure  
<222> (65)

<220>  
<221> unsure  
<222> (70)

<220>  
<221> unsure  
<222> (77)

<220>  
<221> unsure  
<222> (82)

<220>  
<221> unsure  
<222> (84)

<220>  
<221> unsure  
<222> (94)

<220>  
<221> unsure  
<222> (113)

<220>  
<221> unsure  
<222> (132)

<220>  
 <221> unsure  
 <222> (144)

<220>  
 <221> unsure  
 <222> (155)

<220>  
 <221> unsure  
 <222> (165)

<220>  
 <221> unsure  
 <222> (171)

<220>  
 <221> unsure  
 <222> (183)

<220>  
 <221> unsure  
 <222> (198)

<220>  
 <221> unsure  
 <222> (216)

<220>  
 <221> unsure  
 <222> (234)

<220>  
 <221> unsure  
 <222> (249)

<220>  
 <221> unsure  
 <222> (254)

<220>  
 <221> unsure  
 <222> (256)

<400> 25  
 ttttaaaaaa cttttatctt cttggccagg ggaaaggnc cccaggcaan ctgggggtn 60  
 gananaccca naaaacnatg gnanceccaa ccancagggc cagggttacag tgnaactccc 120  
 cagtgggccc cnttatggga ctcnattcag ttaanattta tctancttca nagggacacc 180  
 cancccaaca gttccccnct ggggagtggc ccccanttca acctctggcc ttantttaaa 240  
 aaattaaant ttnanaaag tttttcttac taaaagggaa aaaaaaaaaa aaaaaaaaaa 300  
 aaaaaaaaaa aaaa 314

<210> 26  
 <211> 533  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> unsure

<222> (32)

<220>

<221> unsure

<222> (38)

<400> 26

```

gggatatccc atacaggtat gaaaaaaccc cntatgtnat agtgttctat agcacacaat 60
accttatgaa ggaaggggttt satgaatata tggcagaaga caatcatgaa agamttatyt 120
tgaggggyta gaartaatga gtttggaggt gtgcccctta ggtcctgart gtcctgggat 180
ccctmaccce taattttctct cccaragcat yatcccttct cagtattggt actacatgat 240
tgaactttcc ttctastggt ccctgytctt cagcattgcc tctgatgtcw agcgaaagga 300
ttttaaggaa cagatcatcc accatgtggc cactatcatt ctctctgct tctcctgggt 360
tgccaattac gtccgggcag ggaccctcat catggctctg catgacgctt ctgactacct 420
gctggagtct gccaaagatgt ttaactacgc gggatggaag aacacctgca acaacctctt 480
cattgtgttc gccatcggtt tcatcatcac tcggctggtt atcatgcctt tct 533

```

<210> 27

<211> 44

<212> PRT

<213> Mus musculus

<400> 27

```

Met Thr Leu Leu Thr Thr Cys Trp Ser Leu Pro Arg Cys Leu Thr Thr
  1                      5                      10                      15
Arg Asp Gly Arg Thr Pro Ala Thr Thr Ser Ser Leu Cys Ser Pro Ser
                20                      25                      30
Phe Ser Ser Ser Leu Gly Trp Leu Ser Cys Leu Ser
                35                      40

```

<210> 28

<211> 313

<212> DNA

<213> Mus musculus

<220>

<221> unsure

<222> (4)

<220>

<221> unsure

<222> (33)

<220>

<221> unsure

<222> (35)

<220>

<221> unsure

<222> (94)

<220>

<221> unsure

<222> (226)

<400> 28

```

aaanacaagt caatgaagtg aaggagggtg tgnanacatg cccctcacca taccacaggg 60

```

```

accatgggttc ctaggatctc actgcctccc ttnttggcct tcctgtcccc tcccttcagc 120
tatgacagct ggtgtggagt agaagggcaa ctagtctgt tatttattga acatttggg 180
tttcagttgt aaagccacaa ctacaggtag gacctgatat ttcgngagg gaccatttca 240
gaccaaaatg tactgttaat tttttttaat taaagtatat taaaggttaa ataaaaaaaa 300
aaaaaaaaaa aaa 313

```

<210> 29  
 <211> 525  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> unsure  
 <222> (22)

<220>  
 <221> unsure  
 <222> (52)

<220>  
 <221> unsure  
 <222> (55)

<220>  
 <221> unsure  
 <222> (59)

```

<400> 29
aaagacatcc actttgcctt tntctccaca ggtgtccact cccaggtcca antgnaggng 60
agcctgaatt cggccaaaga ggcctaatta caatcatttc aaattttgaa tttttaagtt 120
gatgggctct taagtgggcc gttctgaata raaaccaatt tgctagtctt gggtttgttt 180
tggtttgttt tggtttgttt tggtttgttt ttttaaggaa tcagatagcc agaaaaaaaa 240
atgctattgc ttgttttcat gaacttcagt tgtctctttt tagtaaacc agtactttcc 300
acaaagtctt ctctgacctt ccccatcact ggacgggtca cccatcttct tctccaagt 360
tttatcccc agcccaagcc tttctgctg caagccaagc ctgctacatt tgttacagac 420
caagcttata cacagctcga caactgcact cccactgtag gctccggtgt gtactcttgt 480
cttgtgttgg gaaggggaag tgaagtgata agccagaatt ttttt 525

```

<210> 30  
 <211> 95  
 <212> PRT  
 <213> Mus musculus

```

<400> 30
Met Leu Leu Leu Val Phe Met Asn Phe Ser Cys Leu Phe Leu Val Asn
  1             5             10             15

Pro Val Leu Ser Thr Lys Ser Ser Leu Thr Phe Pro Ile Thr Gly Arg
      20             25             30

Phe Thr His Leu Leu Leu Gln Val Phe Ile Pro Gln Pro Lys Pro Phe
      35             40             45

Leu Leu Gln Ala Lys Pro Ala Thr Phe Val Thr Asp Gln Ala Tyr Thr
      50             55             60

Gln Leu Asp Asn Cys Thr Pro Thr Val Gly Ser Gly Val Tyr Ser Cys
      65             70             75             80

Leu Val Leu Gly Arg Gly Ser Glu Val Ile Ser Gln Asn Phe Phe

```



85

90

95

<210> 31  
 <211> 270  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> unsure  
 <222> (47)

<220>  
 <221> unsure  
 <222> (71)

<220>  
 <221> unsure  
 <222> (91)

<220>  
 <221> unsure  
 <222> (94)

<220>  
 <221> unsure  
 <222> (105)

<220>  
 <221> unsure  
 <222> (170)

<220>  
 <221> unsure  
 <222> (189)

<220>  
 <221> unsure  
 <222> (192)

<220>  
 <221> unsure  
 <222> (210)

<220>  
 <221> unsure  
 <222> (246)..(247)

<400> 31  
 aggtttcttg ggaacagctc agcagat ttt tgagaccaat caaatgncct cattaagaac 60  
 tttatctggt nggaaacatg gcttccttcc nggntctgct aaacngaaag ctcatttggt 120  
 gttgctgttg ttgttggttg tttgtccatt tctctttaat tctaagttn acatcatgtc 180  
 gtgctgtang antctagaaa gccttaattn acttccacca agaaataaag caatatgttg 240  
 gtaatnngaa aaaaaaaaaa aaaaaaaaaa 270

<210> 32  
 <211> 574  
 <212> DNA  
 <213> Mus musculus

<220>  
<221> unsure  
<222> (9)

<220>  
<221> unsure  
<222> (29)

<220>  
<221> unsure  
<222> (37)

<220>  
<221> unsure  
<222> (53)

<220>  
<221> unsure  
<222> (56)

<220>  
<221> unsure  
<222> (68)

<220>  
<221> unsure  
<222> (72)

<220>  
<221> unsure  
<222> (85)

<220>  
<221> unsure  
<222> (118)

<220>  
<221> unsure  
<222> (131)

<220>  
<221> unsure  
<222> (169) .. (170)

<220>  
<221> unsure  
<222> (172)

<220>  
<221> unsure  
<222> (180)

<220>  
<221> unsure  
<222> (253)

<220>  
<221> unsure  
<222> (448)

<220>  
 <221> unsure  
 <222> (452)

<220>  
 <221> unsure  
 <222> (455)

<220>  
 <221> unsure  
 <222> (457)

<220>  
 <221> unsure  
 <222> (459)

<220>  
 <221> unsure  
 <222> (475)

<220>  
 <221> unsure  
 <222> (550)

<220>  
 <221> unsure  
 <222> (572)

<400> 32  
 tttggtcana aaagacaatt tttttgttnt caagctngag gtgtggcagg ctnganattt 60  
 ggccaaanaa tngagggaca aaganatcca ctttgccctt ttttccacag gtgtccantc 120  
 ccagggtccaa ntgcaggcgg gtccacaggc cgcagccatg ggtagccggn tntcccagn 180  
 ggarttcgaa tgggtytaca cggaccarcc ccacgcgcgc cggcgcaagg agatcttagc 240  
 aaagtatcca ganatcaagt ccttgatgaa acctgaccac aatctgatct ggattgtagc 300  
 catgatgctt ctcgctccagc tggcttcatt ttacttagtc aaagatttgg actggaaatg 360  
 ggtcatatth tggctctatg tctttggcag ctgccttaac cactccatga ctctggctat 420  
 ccatgagatt tcccacaatt tccccttngg cncncnang gcctgtggaa ccgcnngttt 480  
 ggaatgtttg ctaacctctc tctccgaatg gcctactcca tttcctttaa aaaaaacaca 540  
 tggatcacen ccggtactcc gaacggataa antr 574

<210> 33  
 <211> 138  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> UNSURE  
 <222> (5)

<220>  
 <221> UNSURE  
 <222> (8)

<220>  
 <221> UNSURE  
 <222> (32)

<220>  
 <221> UNSURE  
 <222> (97)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (99)..(101)

&lt;400&gt; 33

Met Gly Ser Arg Xaa Ser Arg Xaa Glu Phe Glu Trp Val Tyr Thr Asp  
 1 5 10 15

Gln Pro His Ala Ala Arg Arg Lys Glu Ile Leu Ala Lys Tyr Pro Xaa  
 20 25 30

Ile Lys Ser Leu Met Lys Pro Asp His Asn Leu Ile Trp Ile Val Ala  
 35 40 45

Met Met Leu Leu Val Gln Leu Ala Ser Phe Tyr Leu Val Lys Asp Leu  
 50 55 60

Asp Trp Lys Trp Val Ile Phe Trp Ser Tyr Val Phe Gly Ser Cys Leu  
 65 70 75 80

Asn His Ser Met Thr Leu Ala Ile His Glu Ile Ser His Asn Phe Pro  
 85 90 95

Xaa Gly Xaa Xaa Xaa Ala Cys Gly Thr Ala Gly Leu Glu Cys Leu Leu  
 100 105 110

Thr Ser Leu Ser Glu Trp Pro Thr Pro Phe Pro Leu Lys Lys Thr His  
 115 120 125

Gly Ser Pro Pro Val Leu Arg Thr Asp Lys  
 130 135

&lt;210&gt; 34

&lt;211&gt; 216

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (69)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (86)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (114)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (116)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (119)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (142)

&lt;400&gt; 34

```

atgaagtgct ttttggagga gcttttgttt agtccaacag gagtccaagg atgcagatta 60
gagttttgng agtttctgtc ccttgntggg ctaggcattt cattgttgta actnontcng 120
agtaactgat gatcctataa gnaaccccaa taaatttttt ggtttactaa aaaaaaaaaa 180
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 216

```

&lt;210&gt; 35

&lt;211&gt; 526

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (6)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (25)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (53)

&lt;400&gt; 35

```

acaggngtcc aatcccaggt ccaantgcag gggagcctga attcggccaa agnggcctag 60
cctcccaagt gstgggatta aaggsctgtg ccaccatgcc ccacttcata tgttatattt 120
ttaatgaata aagagtggaa aaattatgta tcacatgtgt taatttgggg agaagcgctt 180
tataacagag ggcttactyt caattaaaga gaacaaaggr aaatgtgtty tacaggcagt 240
gtataccttt gacctctgaa aaaacctata tagtttctcc tacagacacc ttgccagtaa 300
ccttacaggt cttataggag agcagatcca agttgccagg ctgatctgca agcacaacaa 360
tttgtcaagg gaaagcacag gtcgttactt tcagtacaaa atggttcttt gctatggatg 420
gattctcttc ttcttgcccc atgtcctgtt cccaaggacc gacttctctg agcactgtgg 480
tggactcttc tatgaggaga caacatctgg gccttattca atagcc 526

```

&lt;210&gt; 36

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 36

```

Met Val Leu Cys Tyr Gly Trp Ile Leu Phe Phe Leu Pro His Val Leu
  1             5             10             15

```

```

Phe Pro Arg Thr Asp Phe Leu Gln His Cys Gly Gly Leu Phe Tyr Glu
  20             25             30

```

```

Glu Thr Thr Ser Gly Pro Tyr Ser Ile Ala
  35             40

```

&lt;210&gt; 37

&lt;211&gt; 208

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; unsure

<222> (8)

<220>

<221> unsure

<222> (29)

<220>

<221> unsure

<222> (31)

<220>

<221> unsure

<222> (42)

<220>

<221> unsure

<222> (55)

<220>

<221> unsure

<222> (65)

<220>

<221> unsure

<222> (75)

<220>

<221> unsure

<222> (86)

<220>

<221> unsure

<222> (91)

<220>

<221> unsure

<222> (98)

<220>

<221> unsure

<222> (100)..(101)

<220>

<221> unsure

<222> (113)

<220>

<221> unsure

<222> (119)

<220>

<221> unsure

<222> (121)

<220>

<221> unsure

<222> (128)

<220>

<221> unsure

<222> (130)..(131)

<220>

<221> unsure

<222> (133)

<220>

<221> unsure

<222> (137)

<220>

<221> unsure

<222> (161)

<400> 37

```
tttgaangg caacagaaat attttttgna ntagaaaaag gnatggaacg tggtnccaat 60
tgtnatttt ccttnattta ttcccngrta ntttgtcngn ngataaattg aanataacng 120
ngattaangn ntnatgntaa aaaaaaaaaa aaaaaaaaaa naaaaaaaaa aaaaaaaaaa 180
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa                                208
```

<210> 38

<211> 535

<212> DNA

<213> Mus musculus

<220>

<221> unsure

<222> (6)

<220>

<221> unsure

<222> (30)

<220>

<221> unsure

<222> (60)

<220>

<221> unsure

<222> (67)

<220>

<221> unsure

<222> (83)

<220>

<221> unsure

<222> (99)

<220>

<221> unsure

<222> (115)

<220>

<221> unsure

<222> (145)

<220>

<221> unsure

<222> (160)

<220>  
 <221> unsure  
 <222> (165)

<400> 38  
 atttgnctag aaaagacaat ttttttgttn tcaagcttga ggtgtggcag gcttgagatn 60  
 tgcccanaca cttgagggac aangacatcc aataaccent tctctccaca ggtgnccact 120  
 cccaggtcca actgcaggcg agccngaatt cggccaaagn ggccnaagat cagttagctc 180  
 cctgggtcgg aacaagggtga aaagcagctt tcttgctttt gaaatcatyt ttgtgacaag 240  
 gacacatggg gtcagggtag ggtgtccart taaaatagtg tcaactgctta gaaaggggwa 300  
 cttggattcc tttagtttagc ttagctctgt ctcttgtttc ataaaacaca ctggggttaga 360  
 ataraggctc ctgcattaca tggtttgtgt cactgttttt tgttgggttt tcttttttgt 420  
 ttttcgagac agggttttctc tgtatagccc tggctgtcct araactcact ctgtagacca 480  
 ggctggcctc gaactcagaa atctgcccgc ttctgcctcc caagtgtctg gatta 535

<210> 39  
 <211> 52  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> UNSURE  
 <222> (28)

<400> 39  
 Met Val Cys Val Thr Val Phe Cys Trp Val Phe Phe Leu Val Phe Arg  
           1                  5                  10                  15  
 Asp Arg Val Ser Leu Tyr Ser Pro Gly Cys Pro Xaa Thr His Ser Val  
                   20                  25                  30  
 Asp Gln Ala Gly Leu Glu Leu Arg Asn Leu Pro Ala Ser Ala Ser Gln  
           35                  40                  45  
 Val Leu Gly Leu  
           50

<210> 40  
 <211> 308  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> unsure  
 <222> (43)

<220>  
 <221> unsure  
 <222> (115)

<220>  
 <221> unsure  
 <222> (134)

<400> 40  
 ggattaaagg catgtgtcac gttttaaatt gatagttata acntcgatgc cacgaatcct 60  
 gcagtttctc ctgtgtcctt ttctttgtgt cagatgggtt aagggttatc agttngggga 120  
 agaattgtcc ttgnaccccc tggatttatt tttctcaaaa atccaagact ccaaagaaca 180



tgggaaaaaat tgttctgtcc accttttgacg ttgaagattt tggttatcct tttcgtactt 240  
 tctatgtatt ttctatgtaa aatttttacac aattaaaaat gtttttttgt ctagtaaaaa 300  
 aaaaaaaa 308

<210> 41  
 <211> 1351  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> unsure  
 <222> (134)

<400> 41  
 cagcgcgcgg agccggcgct ccgttggcgc gctctggcct ggcttcgggt cgctcgcttcg 60  
 gccccgagga gccgctcgct gtctccggag cggcggagag gatggtgcgg ggcagcccg 120  
 ggcccgccgc gcgcccgcgc gactgaacag ggccaggccg cgggcgtccg cgggctcgar 180  
 ccgccagtct gcggggcggt tgccgctggt gggaagcatg ttcagtatca accccctgga 240  
 gaacctgaag ctgtacatca gcagccggcc gcccttggtg gtttttatga tcagtgtcag 300  
 cgccatggcc atcgcttcc tcacctggg ctacttcttc aagatcaagg agattaagtc 360  
 cccagaaatg gctgaggatt ggaatacttt tctgctccg tttaatgatt tggacttggt 420  
 tgatcagaa aacgagacac tgaagcatct ctccaacgat accaccacac cagagagcac 480  
 catgaccgtc ggcagggcca gatcgtctac ccagccgcc cagtccttgagg agagtcagg 540  
 ccccatcaat atttcagtgg ccattacctt gaccttgga cctctcaagc cctttggagg 600  
 gtactctcga aatgttacac acctgtactc caccatcctc gggcatcaga ttggattgtc 660  
 aggcagggaa gccacgagg agatcaacat caccttcacc ctgcctgctg cctggaacgc 720  
 cgatgactgt gccctccatg gccactgtga gcaggcgggt ttcacagcat gcatgacctt 780  
 cacagctgcc cccggagtct tccccgtcac tgttcagcca cctcactgta tccccgacac 840  
 atacagcaac gccacgctct ggtacaagat cttcacaact gccagagatg ccaacacgaa 900  
 atatgctcaa gactacaatc ctttctgggt ttataagggt gccattggga aagtctacca 960  
 tgctttaaat cccaaactca ctgttggtgt tccagatgac gaccgctcat taataaacct 1020  
 gcatctcatg cacaccagtt acttcctttt cgtgatgggt ataacgatgt tctgctatgc 1080  
 agtcacaaaa gccagaccca gcaaaactgcg gcagagcaat cctgaatttt gccmtgagaa 1140  
 ggtggytctg gctgacgcct aatcctacag ctccccattt tytgagagac caagaacct 1200  
 gatcattgcc tgctgaatcg gccagggcct ggccactctg tgaatacatg atcttgcaat 1260  
 gttgggttat tccagccaaa gacatttcaa gtgcctgtaa ctgatttgtc catatttata 1320  
 aacctgac tggnaaaaaa aaaaaaaaaa a 1351

<210> 42  
 <211> 314  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> UNSURE  
 <222> (306)

<220>  
 <221> UNSURE  
 <222> (310)

<400> 42  
 Met Phe Ser Ile Asn Pro Leu Glu Asn Leu Lys Leu Tyr Ile Ser Ser  
 1 5 10 15  
 Arg Pro Pro Leu Val Val Phe Met Ile Ser Val Ser Ala Met Ala Ile  
 20 25 30  
 Ala Phe Leu Thr Leu Gly Tyr Phe Phe Lys Ile Lys Glu Ile Lys Ser  
 35 40 45

Pro Glu Met Ala Glu Asp Trp Asn Thr Phe Leu Leu Arg Phe Asn Asp  
 50 55 60  
 Leu Asp Leu Cys Val Ser Glu Asn Glu Thr Leu Lys His Leu Ser Asn  
 65 70 75 80  
 Asp Thr Thr Thr Pro Glu Ser Thr Met Thr Val Gly Gln Ala Arg Ser  
 85 90 95  
 Ser Thr Gln Pro Pro Gln Ser Leu Glu Glu Ser Gly Pro Ile Asn Ile  
 100 105 110  
 Ser Val Ala Ile Thr Leu Thr Leu Asp Pro Leu Lys Pro Phe Gly Gly  
 115 120 125  
 Tyr Ser Arg Asn Val Thr His Leu Tyr Ser Thr Ile Leu Gly His Gln  
 130 135 140  
 Ile Gly Leu Ser Gly Arg Glu Ala His Glu Glu Ile Asn Ile Thr Phe  
 145 150 155 160  
 Thr Leu Pro Ala Ala Trp Asn Ala Asp Asp Cys Ala Leu His Gly His  
 165 170 175  
 Cys Glu Gln Ala Val Phe Thr Ala Cys Met Thr Leu Thr Ala Ala Pro  
 180 185 190  
 Gly Val Phe Pro Val Thr Val Gln Pro Pro His Cys Ile Pro Asp Thr  
 195 200 205  
 Tyr Ser Asn Ala Thr Leu Trp Tyr Lys Ile Phe Thr Thr Ala Arg Asp  
 210 215 220  
 Ala Asn Thr Lys Tyr Ala Gln Asp Tyr Asn Pro Phe Trp Cys Tyr Lys  
 225 230 235 240  
 Gly Ala Ile Gly Lys Val Tyr His Ala Leu Asn Pro Lys Leu Thr Val  
 245 250 255  
 Val Val Pro Asp Asp Asp Arg Ser Leu Ile Asn Leu His Leu Met His  
 260 265 270  
 Thr Ser Tyr Phe Leu Phe Val Met Val Ile Thr Met Phe Cys Tyr Ala  
 275 280 285  
 Val Ile Lys Gly Arg Pro Ser Lys Leu Arg Gln Ser Asn Pro Glu Phe  
 290 295 300  
 Cys Xaa Glu Lys Val Xaa Leu Ala Asp Ala  
 305 310

&lt;210&gt; 43

&lt;211&gt; 848

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; unsure

<222> (11)

<220>

<221> unsure

<222> (30)

<220>

<221> unsure

<222> (137)

<220>

<221> unsure

<222> (183)

<220>

<221> unsure

<222> (370)

<220>

<221> unsure

<222> (649)

<220>

<221> unsure

<222> (712)

<220>

<221> unsure

<222> (725)

<220>

<221> unsure

<222> (727)

<220>

<221> unsure

<222> (729)

<220>

<221> unsure

<222> (746)

<220>

<221> unsure

<222> (760)

<220>

<221> unsure

<222> (840)

<400> 43

```

agctgtttggg ntgcggttg aggacaaatn ttgcggtct ttccagtatt cttggatcgg 60
aaacccgtcg gcttccgaac ggtactccgc caccgaggga cctgagcgag tccgcatcga 120
ccggatcgga aaacctntcg actgttgggg tgagtactcc ctctcaaaag cgggcatgac 180
ttntgcgcta agattgtcag tttccaaaaa cgaggaggat ttgatattca cctggcccgc 240
ggtgatgcct ttgagggttg ccgcgtccat ctggtcagaa aagacaatct tttgttgtc 300
aagcttgagg tgtggcaggc ttgagatctg gccatacact tgagtgacaa tgacatccac 360
tttgcccttn tctccacagg tgtccactcc cagggtccaac tgcagacttc gaattcggcc 420
aaagaggcct actttcatat ccacgatgcg ttttctggcc gccacgatcc tgctgctggc 480
gctggtcgct gccagccagg cggagccccc gcaattcaag gactgcggct ctaaggtggg 540

```

agttataaag gaggtgaatg tgagcccatg tcccaccgat ccctgtcagc tgcacaaagg 600  
 ccagtcctac agtgtcaaca tcacctttac cagcggcact cagtccana acagcacggc 660  
 cttgggtccac ggcattcctgg aagggatccg ggtccccttc cctattcctg ancctgacgg 720  
 ttgtnanant ggaatcaact gcccctcca gaaagacaan gtctacagct acctgaataa 780  
 gcttccgggtg aaaaatgaat acccctctat aaaactgggtg gtggaatgga aactttgaan 840  
 atgacaaa 848

<210> 44  
 <211> 130  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> UNSURE  
 <222> (68)

<220>  
 <221> UNSURE  
 <222> (89)

<220>  
 <221> UNSURE  
 <222> (94) .. (95)

<220>  
 <221> UNSURE  
 <222> (101)

<220>  
 <221> UNSURE  
 <222> (105)

<400> 44  
 Met Arg Phe Leu Ala Ala Thr Ile Leu Leu Leu Ala Leu Val Ala Ala  
 1 5 10 15  
 Ser Gln Ala Glu Pro Leu His Phe Lys Asp Cys Gly Ser Lys Val Gly  
 20 25 30  
 Val Ile Lys Glu Val Asn Val Ser Pro Cys Pro Thr Asp Pro Cys Gln  
 35 40 45  
 Leu His Lys Gly Gln Ser Tyr Ser Val Asn Ile Thr Phe Thr Ser Gly  
 50 55 60  
 Thr Gln Ser Xaa Asn Ser Thr Ala Leu Val His Gly Ile Leu Glu Gly  
 65 70 75 80  
 Ile Arg Val Pro Phe Pro Ile Pro Xaa Pro Asp Gly Cys Xaa Xaa Gly  
 85 90 95  
 Ile Asn Cys Pro Xaa Gln Lys Asp Xaa Val Tyr Ser Tyr Leu Asn Lys  
 100 105 110  
 Leu Pro Val Lys Asn Glu Tyr Pro Ser Ile Lys Leu Val Val Glu Trp  
 115 120 125  
 Lys Leu  
 130

<210> 45  
<211> 265  
<212> DNA  
<213> Mus musculus

<220>  
<221> unsure  
<222> (2)

<220>  
<221> unsure  
<222> (67)

<220>  
<221> unsure  
<222> (75)

<220>  
<221> unsure  
<222> (79)

<220>  
<221> unsure  
<222> (101)

<220>  
<221> unsure  
<222> (104)

<220>  
<221> unsure  
<222> (111)

<220>  
<221> unsure  
<222> (121)

<220>  
<221> unsure  
<222> (133)

<220>  
<221> unsure  
<222> (136)

<220>  
<221> unsure  
<222> (157)

<220>  
<221> unsure  
<222> (162)

<220>  
<221> unsure  
<222> (164)

<220>  
<221> unsure

<222> (172)

<220>

<221> unsure

<222> (175)

<220>

<221> unsure

<222> (183)

<220>

<221> unsure

<222> (187)

<220>

<221> unsure

<222> (192)

<220>

<221> unsure

<222> (199) .. (200)

<220>

<221> unsure

<222> (208)

<220>

<221> unsure

<222> (211)

<220>

<221> unsure

<222> (223)

<220>

<221> unsure

<222> (225)

<220>

<221> unsure

<222> (227)

<220>

<221> unsure

<222> (243) .. (244)

<220>

<221> unsure

<222> (246)

<400> 45

```

gngttacctc ccctgtttct aagtgcctcc tgagtcccca gcccctggct tatcagtcag 60
atgagtnctc ttggnagcnt ctgccccatc gcttcagcag nagnagctag ntttcctcgg 120
natccagact ggntgngggg cagtctgccg cagaaanttg tntntgagtg gntgngtctt 180
tgnggttagc tntcggtcnn tggtagtntt nattaaagcc aanantnggt tgcaaaaaaa 240
aanngnaaaa aaaaaaaaaa aaaaaa 265

```

<210> 46

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 46

tnagatccaa cagtcacgtt cacgaaacc

29

<210> 47

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 47

cncctcgggtt gttgtttgaa gagcaggcg

29

<210> 48

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 48

tngccaaga aactgggttt cacatttaa

29

<210> 49

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 49

gntgaagcat gcccaatttc atttcctct

29

<210> 50  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 50  
antgttctct ggcttgctcag ggaagactg

29

<210> 51  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 51  
tncaagttga gttgtacaga agcccaaga

29

<210> 52  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 52  
gntgtgagaa gaccactcgg tgatgacct

29

<210> 53  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)



<223> biotinylated phosphoramidite residue

<400> 53

tngagtctgg gtggtagaca aatcatgca

29

<210> 54

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 54

anggacggta tatatcacca tgaacaagt

29

<210> 55

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 55

anaggcagga ggagacggga ttgatggtt

29

<210> 56

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 56

anaagcgtca tgcagagcca tgatgaggg

29

<210> 57

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 57  
anaaatgtag caggcttggc ttgcagcag 29

<210> 58  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 58  
angaccatt tccagtccaa atctttgac 29

<210> 59  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 59  
gncaaggtgt ctgtaggaga aactatat 28

<210> 60  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 60  
anccagggct atacagagaa accctgtct 29

<210> 61  
<211> 29  
<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 61

gntcttgaag aagtagccca gggtagga

29

<210> 62

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc\_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 62

cnggtaaagg tgatgttgac actgtagga

29

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/24614

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : US 530/300, 350; 536/23.1, 23.5; 435/69.1, 320.1, 325, 252.3, 254.11; 512/2, 12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, WPIDS

search terms: kenneth jabocs, aj267

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 5,708,157 A (JACOBS et al.) 13 January 1998, especially claims.	1-11
X	Database GenBank, National Library of Medicine, Bethesda, Maryland USA. MARRA et al. Accession Number AA497966, 'vi69e01.rl Stratagene mouse testis (#937308) Mus musculus cDNA clone 917496 5' similar to TR:G1297304 G1297304 CTX', 01 July 1997.	1-3
X	EP 0 606 734 A1 (FOLDES, ROBERT L.) 20 July 1994, especially Figure 1, page 10, lines 1-4 and 27-30, and page 11, lines 3-9 and 34-37.	1-7, 10-11
A	JACOBS et al. A genetic selection for isolating cDNAs encoding secreted proteins. Gene. 01 October 1997, Vol. 198, pages 289-296, entire document.	1-12

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 FEBRUARY 1999

Date of mailing of the international search report

25 FEB 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CLAIRE M. KAUFMAN

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/24614

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/24614

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07K 14/47, 14/00, 7/00; C12N 5/10, 15/10, 15/11, 15/12, 15/63; A61K 38/00

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

US 530/300, 350; 536/23.1, 23.5; 435/69.1, 320.1, 325, 252.3, 254.11; 512/2, 12

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-12, drawn to polynucleotide of clone AJ26\_3, protein, method of making the protein, method comprising administration of the protein, and gene.

Group II, claim(s) 13-15, drawn to polynucleotide of clone AJ172\_2, protein and gene.

Group III, claim(s) 16-18, drawn to polynucleotide of clone AP224\_2, protein and gene.

Group IV, claim(s) 19-21, drawn to polynucleotide of clone BL89\_13, protein and gene.

Group V, claim(s) 22-24, drawn to polynucleotide of clone BL341\_4, protein and gene.

Group VI, claim(s) 25-27, drawn to polynucleotide of clone BV239\_3, protein and gene.

Group VII, claim(s) 28-30, drawn to polynucleotide of clone CC25\_17, protein and gene.

Group VIII, claim(s) 31-33, drawn to polynucleotide of clone CC397\_19, protein and gene.

Group IX, claim(s) 34-36, drawn to polynucleotide of clone D305\_2, protein and gene.

Group X, claim(s) 37-39, drawn to polynucleotide of clone G55\_1, protein and gene.

Group XI, claim(s) 40-42, drawn to polynucleotide of clone K39\_7, protein and gene.

Group XII, claim(s) 43-45, drawn to polynucleotide of clone K330\_3, protein and gene.

Group XIII, claim(s) 46-48, drawn to polynucleotide of clone K363\_3, protein and gene.

Group XIV, claim(s) 49-51, drawn to polynucleotide of clone K446\_3, protein and gene.

Group XV, claim(s) 52-54, drawn to polynucleotide of clone K464\_4, protein and gene.

Group XV, claim(s) 55-57, drawn to polynucleotide of clone K483\_1, protein and gene.

Group XVI, claim(s) 58-60, drawn to polynucleotide of clone KL69\_3, protein and gene.

The inventions listed as Groups I-XVI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the main invention in the instant application comprises the first-recited product and the method of using the product, as well as products produced by the method and method of using the products. Further, pursuant to 37 CFR 1.475(b)-(d), the ISA/US considers that each group is drawn to a different polynucleotide and related protein and gene, so the groups lack the same or corresponding special technical feature within the meaning of PCT Rule 13.2, and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.